DRUG NAME: Cefuroxime

ℹ️ Available as two distinct salt forms with clinically significant differences:

Salt Form	Route	Chemical Nature	Notes
Cefuroxime Sodium	IV, IM	Active drug (not a prodrug)	Parenteral formulation — immediate bioavailability
Cefuroxime Axetil	Oral	Prodrug — acetoxyethyl ester of cefuroxime	Hydrolysed during absorption in the intestinal mucosa and blood to release active cefuroxime. The ester linkage improves oral absorption (acid stability) but bioavailability remains moderate (~37–52%). ⚠️ Must be taken WITH food — food increases bioavailability by ~40–50%. This is the OPPOSITE of many other oral antibiotics that require empty stomach (e.g., cloxacillin, dicloxacillin, ampicillin).

ℹ️ Throughout this monograph: Parenteral doses refer to cefuroxime sodium. Oral doses refer to cefuroxime axetil (expressed as cefuroxime base equivalent unless otherwise stated). When the text says “cefuroxime” without specifying the salt, both forms are implied unless context makes it clear.

ℹ️ Class positioning: Cefuroxime is a second-generation cephalosporin — positioned between:

First-generation (cefazolin IV, cephalexin oral) — excellent gram-positive (MSSA) + limited gram-negative
Second-generation (cefuroxime IV/oral, cefaclor oral) — good gram-positive + enhanced gram-negative (particularly H. influenzae including beta-lactamase producers, M. catarrhalis)
Third-generation (ceftriaxone IV, cefixime oral, cefpodoxime oral) — broader gram-negative + better CSF penetration; reduced gram-positive activity

💡 The KEY clinical advantage of cefuroxime over first-generation cephalosporins:
Cefuroxime is stable against beta-lactamases produced by Haemophilus influenzae and Moraxella catarrhalis — two organisms that are major causes of:

Community-acquired pneumonia (CAP)
Acute otitis media (AOM) — extremely common in Indian children
Acute bacterial sinusitis
Acute exacerbation of COPD (AECOPD)

First-generation cephalosporins (cefazolin, cephalexin) have unreliable activity against H. influenzae — particularly beta-lactamase-producing strains, which constitute 20–40% of H. influenzae isolates in India. This gap is what makes cefuroxime clinically relevant for respiratory infections.

💡 Why cefuroxime still matters in Indian practice (despite the dominance of ceftriaxone/cefixime):
In India, third-generation cephalosporins — particularly injectable ceftriaxone and oral cefixime — are heavily overused for a wide range of infections. Cefuroxime occupies an important antimicrobial stewardship niche:

It is a narrower-spectrum alternative to ceftriaxone for non-severe community-acquired infections where gram-negative coverage beyond first-generation is needed but third-generation breadth is unnecessary.
Oral cefuroxime axetil is a reasonable alternative to oral cefixime for mild-moderate respiratory and urinary infections — with better gram-positive (MSSA, pneumococcal) coverage.
Using cefuroxime when appropriate (instead of defaulting to ceftriaxone) preserves third-generation cephalosporin efficacy and reduces selection pressure for ESBL and AmpC resistance — a critical concern in Indian hospitals.

Therapeutic Class:

Antibiotic (Anti-infective)

Subclass:

Second-Generation Cephalosporin

ℹ️ Cefuroxime is the only second-generation cephalosporin available in India in both parenteral AND oral formulations — making it uniquely suitable for IV-to-oral step-down within the same drug (no need to switch to a different molecule for oral step-down, unlike cefazolin which requires switching to cephalexin).

Schedule (India):

Schedule H
All parenteral (IV/IM) and oral (tablets, dry syrup) formulations of cefuroxime are classified under Schedule H of the Drugs and Cosmetics Act. Dispensing requires a valid prescription from a registered medical practitioner. No OTC formulations exist.

Route(s)

Intravenous (IV) — slow IV injection (bolus) or intermittent IV infusion (as cefuroxime sodium)
Intramuscular (IM) — deep IM injection (as cefuroxime sodium; acceptable alternative when IV access unavailable)
Oral — tablets and dry syrup/suspension (as cefuroxime axetil — a prodrug)

ℹ️ Unique dual-formulation advantage: Cefuroxime is the only second-generation cephalosporin in India available as both IV/IM (cefuroxime sodium) and oral (cefuroxime axetil), allowing seamless IV-to-oral step-down within the same molecule. This eliminates the pharmacological uncertainty of switching between different molecules for step-down (e.g., cefazolin IV → cephalexin oral = same generation but different molecule; ceftriaxone IV → cefixime oral = different generation and spectrum).

Biosimilar Status:

Not a biologic — biosimilar classification not applicable. This is a small-molecule chemical drug. Multiple generic versions are approved by CDSCO and widely available in India.

Formulations Available in India

A. Parenteral Formulations — Cefuroxime Sodium

Powder for Injection (Reconstitution Required):

Strength (as Cefuroxime Base Equivalent)	Route	Notes
250 mg vial	IV / IM	Primarily paediatric; less commonly stocked
750 mg vial	IV / IM	Standard adult vial — most commonly stocked across Indian hospitals. ✅ NLEM-listed strength.
1.5 g vial	IV / IM	Higher-dose vial for severe infections and surgical prophylaxis. ✅ NLEM-listed strength.

ℹ️ The 750 mg and 1.5 g vials are the most widely stocked across Indian hospitals. The 250 mg vial has variable availability.

B. Oral Formulations — Cefuroxime Axetil (Prodrug)

Film-Coated Tablets:

Strength (as Cefuroxime Base Equivalent)	Notes
125 mg	Paediatric/low-dose adult strength
250 mg	Standard adult strength for mild infections
500 mg	Standard adult strength for moderate infections

ℹ️ Tablets must be swallowed whole — do NOT crush. Cefuroxime axetil tablets have a strong, bitter taste when crushed. The film coating masks this bitterness and also protects the ester bond from premature hydrolysis. Crushing destroys the coating → bitter taste → poor compliance (especially in children) AND potentially reduced bioavailability.

Dry Syrup / Powder for Oral Suspension (Cefuroxime Axetil):

Per 5 mL (after reconstitution)	Typical Bottle Size	Notes
125 mg/5 mL	30 mL / 50 mL	Standard paediatric strength. ⚠️ Taste: Even in suspension form, cefuroxime axetil has a notably bitter/unpleasant taste that is difficult to mask completely. This is one of the most common reasons for poor paediatric compliance. Some manufacturers add flavouring, but palatability remains a challenge.

ℹ️ Paediatric formulation availability: Oral suspension is available from multiple Indian manufacturers but its bitter taste is a well-recognised clinical problem. Alternative oral second/third-generation cephalosporins with better palatability include cefpodoxime proxetil suspension and cefixime suspension — both are more palatable and commonly prescribed for children in India. The choice between cefuroxime and these alternatives often comes down to taste/compliance vs spectrum considerations.

C. Fixed-Dose Combinations (FDCs)

Cefuroxime Axetil + Clavulanic Acid (Potassium Clavulanate):

Strength	Notes
Cefuroxime 250 mg + Clavulanic acid 125 mg tablet	Available from select manufacturers
Cefuroxime 500 mg + Clavulanic acid 125 mg tablet	Available from select manufacturers

ℹ️ Rationality of cefuroxime + clavulanate FDC — debated:

Proponents argue: Clavulanic acid extends cefuroxime’s coverage to include some beta-lactamase-producing organisms that may be borderline resistant to cefuroxime alone.
Opponents argue: Cefuroxime is ALREADY intrinsically stable against the common respiratory beta-lactamases (TEM-1, SHV-1 from H. influenzae, beta-lactamase from M. catarrhalis) — adding clavulanic acid provides minimal additional benefit for its labelled indications. The FDC adds cost, increases GI adverse effects (clavulanate-driven diarrhoea), and is not supported by major guidelines (ICMR, API Textbook, IDSA) as superior to cefuroxime alone for any standard indication.
Current status: Available in the Indian market from some manufacturers. Not banned by CDSCO. Not included in NLEM. Indian prescribers should use cefuroxime axetil alone for standard indications — the addition of clavulanate is generally unnecessary. If broader beta-lactamase coverage is needed, amoxicillin-clavulanate (a well-validated FDC) is the preferred choice.

D. Formulations NOT Available for Cefuroxime in India

⛔ No topical formulation
⛔ No intrathecal formulation (NOT approved for intrathecal use)
⛔ No ophthalmic formulation (though cefuroxime sodium is used intracamerally in ophthalmology as an off-label preparation — see Secondary Indications in Part 2)

PHARMACOKINETICS

ℹ️ Pharmacokinetic parameters are presented separately for parenteral (cefuroxime sodium) and oral (cefuroxime axetil) routes, as they have distinct absorption characteristics. Once absorbed and hydrolysed, the active moiety (cefuroxime) follows identical distribution, metabolism, and elimination kinetics regardless of route.

Parenteral (IV/IM) — Cefuroxime Sodium

Parameter	Value
Bioavailability	IV: 100%. IM: ~90–95% (well absorbed from deep IM sites).
Tmax	End of infusion (IV); ~45 minutes (IM)

Oral — Cefuroxime Axetil (Prodrug)

Parameter	Value
Prodrug status	✅ Yes — cefuroxime axetil is a prodrug. It is the 1-acetoxyethyl ester of cefuroxime. After oral ingestion, it is rapidly hydrolysed by non-specific esterases in the intestinal mucosa and portal circulation to release active cefuroxime + acetic acid + acetaldehyde. Systemic circulation contains only active cefuroxime — the intact ester is not detectable in plasma.
Bioavailability (oral)	~37–52% (fasting: ~37%; fed: ~52%). ⚠️ MUST be taken WITH food — food increases oral bioavailability by approximately 40–50% (from ~37% to ~52%). This is clinically significant and is one of the most important prescribing/counselling points for oral cefuroxime. The mechanism: food slows gastric emptying, prolonging contact time with intestinal esterases → more complete hydrolysis → more cefuroxime released → higher systemic levels.
Tmax (oral)	~2–3 hours (with food); delayed to ~3–4 hours fasting

Common PK Parameters (Both Routes — After Cefuroxime Is in Systemic Circulation)

Parameter	Value
Protein binding	~33–50% — moderate. ℹ️ This is substantially LOWER than antistaphylococcal penicillins (cloxacillin ~95%, dicloxacillin ~97%) and first-generation cephalosporins (cefazolin ~75–85%). The lower protein binding means a higher free (unbound) drug fraction (~50–67%) — pharmacodynamically advantageous for a time-dependent antibiotic (more free drug available for bactericidal activity).
Volume of distribution (Vd)	~0.2–0.3 L/kg — low-moderate (typical of hydrophilic cephalosporins). Distributes well into: respiratory tract secretions (sputum, bronchial mucosa — basis for respiratory infection treatment), middle ear fluid (basis for otitis media treatment), sinus mucosa, tonsils/adenoids, pleural fluid, joint fluid, bone (moderate), wound exudates, peritoneal fluid, bile (moderate), and renal/urinary tissue. CSF penetration: Moderate with inflamed meninges (~5–15% of serum levels — better than first-generation cephalosporins). Historically used for bacterial meningitis but now superseded by ceftriaxone/cefotaxime (superior CSF penetration and broader gram-negative coverage). ⛔ NOT recommended as first-line for meningitis in current practice.
Metabolism	NOT metabolised. Active cefuroxime is excreted unchanged. There are NO active or inactive metabolites. ℹ️ The oral prodrug (cefuroxime axetil) is hydrolysed PRE-systemically to release active cefuroxime — this is not “metabolism” in the traditional hepatic sense but rather a bioactivation step in the gut wall and blood. Cefuroxime is NOT a substrate, inhibitor, or inducer of CYP450 enzymes. It has NO significant drug transporter interactions (P-gp, OATP, OAT, OCT, MATE, BCRP) at therapeutic concentrations. This gives cefuroxime a very clean drug interaction profile — similar to cefazolin.
Half-life (t½)	~1–2 hours (adults with normal renal function). ℹ️ Intermediate between cefazolin (~1.8–2.5 hours) and the antistaphylococcal penicillins (~0.5–1.5 hours). Supports q8h dosing for most treatment indications (same as cefazolin). Prolonged in renal impairment: up to 10–17 hours in severe CKD (CrCl <10 mL/min). Prolonged in neonates (~3–5 hours) due to immature renal function.
Excretion	Primarily renal: ~85–95% excreted unchanged in urine via glomerular filtration and active tubular secretion (OAT1/OAT3). Achieves very high urinary concentrations — basis for UTI treatment. Minor biliary excretion (~5–10%). ⚠️ Dose adjustment IS required in significant renal impairment (similar to cefazolin).
Dialysability	YES — removed by haemodialysis (~50% removal during a standard 4-hour HD session). Supplemental dose post-HD is REQUIRED. Also removed by CRRT. NOT significantly removed by standard peritoneal dialysis.
Food effect	⚠️ CRITICAL — for ORAL cefuroxime axetil ONLY: Food INCREASES oral bioavailability by ~40–50%. Always take oral cefuroxime WITH food. This is the OPPOSITE of many other oral beta-lactams (cloxacillin, dicloxacillin, ampicillin — which must be taken on empty stomach). For parenteral cefuroxime: food effect is not applicable.
Onset of action	Therapeutic serum levels: immediately with IV bolus; within ~45 min IM; within 2–3 hours oral (with food). Clinical improvement in infections typically within 48–72 hours.
Duration of action	Bactericidal activity is time-dependent (%fT > MIC). The ~1–2 hour half-life combined with the relatively high free drug fraction (~50–67%) means adequate %fT > MIC is maintained with q8h (IV) or q12h (oral) dosing for susceptible organisms.

Non-linear Pharmacokinetics: Not applicable — cefuroxime exhibits linear PK at standard therapeutic doses.

Comparative Pharmacokinetic Table: Cefuroxime vs Other Commonly Used Cephalosporins in India

PK Parameter	Cefuroxime (2nd gen)	Cefazolin (1st gen) — IV only	Cephalexin (1st gen) — oral only	Ceftriaxone (3rd gen) — IV/IM only	Cefixime (3rd gen) — oral only
Both IV + Oral available?	✅ YES — unique advantage	❌ IV only	❌ Oral only	❌ IV/IM only	❌ Oral only
Oral bioavailability	~37–52% (with food)	N/A	~90%	N/A	~40–50%
Food effect (oral)	⚠️ Take WITH food (↑40–50%)	N/A	Minimal	N/A	Minimal
Protein binding	~33–50%	~70–85%	~6–15%	~83–96% (concentration-dependent)	~65–70%
Free drug fraction	~50–67%	~15–30%	~85–94%	~4–17%	~30–35%
Half-life	~1–2 hr	~1.8–2.5 hr	~0.5–1.2 hr	~6–9 hr (longest)	~3–4 hr
Dosing frequency (treatment)	IV: q8h; Oral: q12h	IV: q8h	Oral: q6–8h	IV/IM: q12–24h	Oral: q12–24h
Primary elimination	Renal (~90%)	Renal (~90%)	Renal (~90%)	Renal (~50–60%) + Biliary (~40%)	Renal (~50%) + Biliary/Faecal (~50%)
Renal dose adjustment	⚠️ YES	⚠️ YES	⚠️ YES	✅ Not usually (biliary backup)	✅ Not usually
Hepatic metabolism	✅ None	✅ None	✅ None	✅ None	✅ None
CYP interactions	✅ None	✅ None	✅ None	✅ None	✅ None
H. influenzae coverage	✅ YES (incl. beta-lactamase +)	⚠️ Unreliable	⚠️ Unreliable	✅ YES	✅ YES
MSSA coverage	✅ Good	✅ Excellent	✅ Good	⚠️ Moderate (less than 1st/2nd gen)	⚠️ Poor
Pseudomonas	⛔ No	⛔ No	⛔ No	⛔ No	⛔ No
ESBL coverage	⛔ No	⛔ No	⛔ No	⛔ No	⛔ No
NLEM India 2022	✅ Injection (750 mg, 1.5 g)	✅ Injection (1 g)	✅ Capsule (250/500 mg)	✅ Injection (250 mg, 1 g)	❌ Not listed
CSF penetration	Moderate (~5–15%)	Poor (~1–3%)	Poor	Good (~10–20%)	Poor

Key Clinical PK Distinctions of Cefuroxime

💡 1. The “take with food” rule — UNIQUE among cephalosporins:
Oral cefuroxime axetil is one of the very few oral cephalosporins where food ENHANCES absorption. Most oral antibiotics are either unaffected by food or require empty stomach. Failure to take cefuroxime with food results in subtherapeutic serum levels — potentially causing treatment failure. This is the single most important counselling point for oral cefuroxime.

💡 2. IV-to-oral step-down within the SAME molecule:
Cefuroxime is the only cephalosporin available in India as both IV/IM AND oral formulations. This allows:

IV cefuroxime sodium → Oral cefuroxime axetil (same drug, same spectrum)
No need to change molecules for step-down
Simplifies prescribing and reduces risk of spectrum mismatch during step-down
This is a pharmacological advantage over: cefazolin (IV) → cephalexin (oral) = different molecule; ceftriaxone (IV) → cefixime (oral) = different generation with different spectrum

💡 3. Better respiratory pathogen coverage than first-generation:
Cefuroxime’s stability against H. influenzae and M. catarrhalis beta-lactamases fills a gap between first-generation cephalosporins (which cannot reliably cover these organisms) and third-generation cephalosporins (which are unnecessarily broad for community-acquired respiratory infections). This makes cefuroxime an appropriate antimicrobial stewardship choice for non-severe CAP, AOM, sinusitis, and AECOPD where amoxicillin/amoxicillin-clavulanate has failed or is contraindicated.

Spectrum of Activity

Organism	Activity	Notes
S. aureus — MSSA	✅ Good	Active but less potent than first-generation cephalosporins (cefazolin > cefuroxime for MSSA). Adequate for MSSA SSTIs but NOT the drug of choice for serious MSSA infections (bacteraemia, endocarditis — use cefazolin or cloxacillin).
Coagulase-negative staphylococci (CoNS) — methicillin-susceptible	✅ Good
Streptococcus pyogenes (GAS)	✅ Excellent
Streptococcus pneumoniae	✅ Good (penicillin-susceptible and intermediate)	MIC breakpoints: susceptible ≤1 mg/L (parenteral, non-meningitis); ≤0.5 mg/L (oral). ⚠️ NOT reliably active against penicillin-resistant pneumococcus (MIC >2 mg/L for penicillin) — use ceftriaxone or respiratory fluoroquinolone for resistant pneumococcal infections.
Streptococcus agalactiae (GBS)	✅ Good
Viridans group streptococci	✅ Good (most strains)
Haemophilus influenzae	✅ Excellent — KEY advantage over first-generation	Active against BOTH beta-lactamase-producing AND non-producing strains. This is the principal clinical reason to choose cefuroxime over cefazolin/cephalexin for respiratory infections.
Moraxella catarrhalis	✅ Excellent	Beta-lactamase-producing strains also susceptible. Important respiratory pathogen (AOM, sinusitis, AECOPD).
Neisseria gonorrhoeae	⚠️ Historically active but now UNRELIABLE	⚠️ Gonococcal resistance to cefuroxime has risen significantly in India and globally. Do NOT use cefuroxime for gonorrhoea — current Indian (ICMR/NACO) and international (WHO) guidelines recommend ceftriaxone 500 mg IM single dose as first-line for gonorrhoea.
Neisseria meningitidis	✅ Good	But ceftriaxone is strongly preferred for meningococcal meningitis.
E. coli (non-ESBL)	✅ Good	Community-acquired, non-ESBL strains. ⛔ NOT active against ESBL producers. ⚠️ India-specific: ESBL prevalence among E. coli is 40–70% in hospital settings and 20–40% even in community-acquired UTIs in urban India. Cefuroxime is UNRELIABLE for empiric gram-negative UTI therapy in high-ESBL-prevalence settings without culture guidance.
Klebsiella pneumoniae (non-ESBL)	✅ Moderate-Good	Same ESBL caveat as E. coli — unreliable for empiric therapy in Indian hospital settings.
Proteus mirabilis	✅ Good	Non-ESBL strains
MRSA	⛔ NOT active	mecA-mediated resistance = resistant to ALL cephalosporins
Enterococci	⛔ NOT active	Intrinsic resistance to all cephalosporins
Pseudomonas aeruginosa	⛔ NOT active	No antipseudomonal activity
ESBL-producing Enterobacterales	⛔ NOT active	⚠️ CRITICAL India limitation
Bacteroides fragilis	⛔ NOT active	No useful anaerobic coverage (except some oral anaerobes). For mixed aerobic-anaerobic infections: add metronidazole.
Atypical organisms (Mycoplasma, Chlamydophila, Legionella)	⛔ NOT active	Beta-lactams have no activity against atypicals — for atypical pneumonia, combine with macrolide or use doxycycline/fluoroquinolone.
Borrelia burgdorferi	✅ Good	Cefuroxime axetil is one of the oral drugs of choice for early Lyme disease (erythema migrans). Relevance in India: Lyme disease is uncommon but reported in Himalayan and northeast Indian states.
Listeria monocytogenes	⛔ NOT active	ALL cephalosporins are intrinsically resistant to Listeria

Population Pharmacokinetic Notes

Population	Clinical PK Significance
Obesity	Cefuroxime Vd (~0.2–0.3 L/kg) does not increase proportionally with adipose tissue. Standard doses (750 mg–1.5 g IV) are generally adequate for obese patients with most infections. For surgical prophylaxis in obese patients (BMI >40): consider using the 1.5 g dose rather than 750 mg to ensure adequate tissue concentrations. Data is less established than for cefazolin obesity dosing.
Pregnancy	Increased renal clearance (GFR up to 50% higher) accelerates cefuroxime elimination. Serum levels may be ~20–30% lower than non-pregnant women. Standard doses remain adequate for most infections. Cefuroxime crosses the placenta — fetal exposure occurs but is considered safe (cephalosporin class safety).
Critical illness / ICU	Increased Vd (fluid shifts, capillary leak in sepsis) may reduce serum levels. ARC in young septic/trauma patients can increase clearance. For ICU patients with serious infections: use the higher dose range (1.5 g IV q8h). Consider q6h dosing if ARC confirmed.
Paediatric	Neonates: prolonged half-life (~3–5 hours) due to immature renal function — extended dosing intervals (q8–12h). Infants >1 month and older children: weight-adjusted clearance approaches adult values. Standard weight-based dosing adequate.
Elderly (≥60 years)	Age-related decline in GFR reduces cefuroxime clearance. Half-life prolonged. Dose adjustment per renal function (CrCl calculation essential in elderly — do NOT rely on serum creatinine alone).

Cefuroxime vs Amoxicillin-Clavulanate — The Key Comparator Decision in Indian Practice

ℹ️ This comparison is essential because amoxicillin-clavulanate and cefuroxime compete for many of the same clinical indications in India: CAP, AOM, sinusitis, UTI, SSTI, and surgical prophylaxis.

Feature	Cefuroxime	Amoxicillin-Clavulanate
Oral formulation	Cefuroxime axetil (prodrug; ~37–52% bioavailability)	Amoxicillin-clavulanate (amoxicillin ~75–92% bioavailability; clavulanate ~60–75%)
Food requirement	MUST take WITH food	SHOULD take with food (improves clavulanate absorption, reduces GI effects)
GI adverse effects	Moderate (nausea ~5–10%; diarrhoea ~3–8%)	⚠️ Higher (diarrhoea ~10–25% — clavulanate-driven)
H. influenzae coverage	✅ Excellent (intrinsic beta-lactamase stability)	✅ Excellent (clavulanate inhibits beta-lactamase)
M. catarrhalis coverage	✅ Excellent	✅ Excellent
Anaerobic coverage	⛔ Poor	✅ Good (B. fragilis — most strains)
Enterococcal coverage	⛔ None	✅ E. faecalis (amoxicillin component)
IV formulation available	✅ Yes (cefuroxime sodium)	✅ Yes (amoxicillin-clavulanate IV)
IV-to-oral step-down	✅ Same molecule (cefuroxime sodium → cefuroxime axetil)	✅ Same combination (IV → oral amoxicillin-clavulanate)
Taste (paediatric suspension)	⚠️ Bitter — major compliance issue	Moderate — better tolerated than cefuroxime
NLEM India 2022	✅ Injection (750 mg, 1.5 g)	✅ Tablet (500/125 mg); Injection (1000/200 mg)
Cost	Moderate	Generally lower (amoxicillin is very affordable)

💡 Clinical decision guide:

If anaerobic coverage is needed (aspiration pneumonia, intra-abdominal, dental, bite wounds): → Amoxicillin-clavulanate is preferred (or cefuroxime + metronidazole).
If enterococcal coverage is needed (UTI with suspected enterococci, peritonitis): → Amoxicillin-clavulanate or ampicillin-based regimen.
If GI tolerability is a priority (history of antibiotic-associated diarrhoea, elderly): → Cefuroxime (lower diarrhoea rate than amoxicillin-clavulanate).
If a single-agent IV-to-oral step-down without anaerobic/enterococcal needs: → Cefuroxime is a clean, efficient choice.
If paediatric palatability matters: → Amoxicillin-clavulanate suspension is better tolerated than cefuroxime suspension (but cefixime or cefpodoxime suspensions are even better tolerated).

ADULT INDICATIONS + DOSING

⚠️ ANTIMICROBIAL STEWARDSHIP NOTES FOR CEFUROXIME IN INDIA

1. Know WHERE cefuroxime fits — between first-generation and third-generation:
Cefuroxime occupies a specific clinical niche: it is for infections where first-generation cephalosporins are insufficient (need H. influenzae / M. catarrhalis coverage) but third-generation cephalosporins are unnecessarily broad (non-severe community-acquired infections). Defaulting to ceftriaxone or cefixime when cefuroxime would suffice drives ESBL resistance — a critical problem in India.

2. Oral cefuroxime axetil — ALWAYS WITH FOOD:
This is the single most important prescribing instruction for oral cefuroxime. Failure to take with food reduces bioavailability by ~40–50% → subtherapeutic levels → treatment failure → unnecessary escalation to broader-spectrum agents. Counsel every patient and write “TAKE WITH FOOD” on every prescription.

3. Do NOT use cefuroxime for:

⛔ MRSA infections (no activity)
⛔ ESBL-producing gram-negative infections (no activity — high prevalence in India)
⛔ Pseudomonas infections (no activity)
⛔ Gonorrhoea (resistance too high — use ceftriaxone per NACO/ICMR guidelines)
⛔ Meningitis as first-line (CSF penetration adequate but inferior to ceftriaxone — use ceftriaxone/cefotaxime)
⛔ Serious/life-threatening MSSA infections (use cefazolin or cloxacillin — better MSSA activity)
⛔ Anaerobic infections (no B. fragilis coverage — add metronidazole if anaerobic component)
⛔ Enterococcal infections (intrinsic resistance)

GENERAL ADULT DOSING REFERENCE TABLE

ℹ️ Parenteral doses: cefuroxime sodium. Oral doses: cefuroxime axetil (as cefuroxime base equivalent).

PARENTERAL (IV/IM):

Dose Tier	Route	Per-Dose	Frequency	Total Daily Dose	Typical Use
Standard	IV or IM	750 mg	Every 8 hours (q8h)	2.25 g/day	Most community-acquired moderate infections
Severe	IV	1.5 g	Every 8 hours (q8h)	4.5 g/day	Severe infections, lower respiratory, bone/joint
Life-threatening	IV	1.5 g	Every 6 hours (q6h)	6 g/day	Life-threatening infections; meningitis (if used — not first-line)
Surgical prophylaxis	IV	1.5 g	Single dose pre-op (± additional doses)	1.5–4.5 g total	See surgical prophylaxis indication below

ORAL (Cefuroxime Axetil):

Dose Tier	Per-Dose	Frequency	Total Daily Dose	Typical Use
Mild	250 mg	Every 12 hours (q12h)	500 mg/day	Mild UTI, mild SSTI, pharyngitis
Standard / Moderate	500 mg	Every 12 hours (q12h)	1 g/day	CAP (outpatient), sinusitis, AOM, AECOPD, moderate UTI/SSTI
Maximum oral	500 mg	Every 12 hours (q12h)	1 g/day (maximum recommended oral dose)	—

⚠️ All oral doses must be taken WITH FOOD.

Mandatory Dose Format:

Starting dose: Full therapeutic dose from first administration (no titration for antibiotics)
Titration: Not applicable
Usual maintenance dose: 750 mg IV q8h (parenteral); 250–500 mg oral q12h (oral)
Maximum dose: Parenteral: Max 1.5 g per dose; Max 6 g per day (q6h). Oral: Max 500 mg per dose; Max 1 g per day.

Primary Indications (Approved / Standard in India)

Indication 1: COMMUNITY-ACQUIRED PNEUMONIA (CAP) — Non-Severe, Hospitalised or Outpatient

Route	Per-Dose	Frequency	Duration	Combination
IV (hospitalised, non-severe — CURB-65 score 1–2)	750 mg–1.5 g	Every 8 hours	Until clinically improving + afebrile ≥48 hrs → oral step-down. Total 5–7 days.	± Macrolide (azithromycin 500 mg IV/oral OD) or doxycycline 100 mg BD for atypical pathogen coverage — recommended for all hospitalised CAP per API Textbook and ICMR guidelines
Oral step-down (from IV)	500 mg cefuroxime axetil	Every 12 hours WITH FOOD	To complete total 5–7 days	± Oral azithromycin or doxycycline (to complete atypical coverage)
Oral (outpatient — non-severe CAP, CURB-65 score 0–1)	500 mg cefuroxime axetil	Every 12 hours WITH FOOD	5–7 days	± Macrolide/doxycycline for atypical coverage (recommended for outpatient CAP with comorbidities or prior antibiotic exposure)

Mandatory Clinical Notes:

When to prefer cefuroxime over alternatives for CAP:
- ✅ When second-line oral therapy is needed (amoxicillin-clavulanate failure or intolerance): cefuroxime axetil oral provides equivalent respiratory pathogen coverage (S. pneumoniae, H. influenzae, M. catarrhalis) with potentially better GI tolerability (less diarrhoea than amoxicillin-clavulanate).
- ✅ When IV-to-oral step-down within the same molecule is desired: cefuroxime sodium IV → cefuroxime axetil oral. Eliminates the spectrum uncertainty of cross-molecule step-down (e.g., ceftriaxone IV → cefixime oral = generation change with spectrum shift).
- ✅ When an antimicrobial stewardship alternative to ceftriaxone is appropriate: for non-severe, community-acquired pneumonia WITHOUT risk factors for gram-negative MDR organisms, cefuroxime provides adequate coverage without the broader gram-negative pressure of third-generation cephalosporins.
When NOT to use cefuroxime for CAP:
- ⛔ Severe CAP (CURB-65 ≥3, ICU admission) — requires broader coverage (piperacillin-tazobactam, ceftriaxone, or carbapenem ± macrolide/fluoroquinolone).
- ⛔ Suspected aspiration pneumonia — cefuroxime has NO anaerobic (Bacteroides) coverage. Use ampicillin-sulbactam, amoxicillin-clavulanate, or clindamycin + ceftriaxone.
- ⛔ Hospital-acquired pneumonia (HAP) / VAP — likely MDR gram-negatives requiring broader agents.
- ⛔ Suspected atypical pneumonia as monotherapy — cefuroxime does NOT cover Mycoplasma, Chlamydophila, Legionella. Must combine with macrolide or doxycycline, or use respiratory fluoroquinolone monotherapy.
- ⛔ Penicillin-resistant pneumococcus (MIC >2 mg/L for penicillin) — cefuroxime MICs may be elevated. Use ceftriaxone or respiratory fluoroquinolone.
- ⛔ Known or suspected ESBL-producing pathogen — cefuroxime is inactive.
NLEM India status: ✅ Cefuroxime injection (750 mg, 1.5 g) IS included in NLEM India 2022. Oral cefuroxime axetil is NOT separately NLEM-listed (but amoxicillin-clavulanate oral IS NLEM-listed as the preferred oral agent for respiratory infections).
Time to expected clinical response: Defervescence and symptom improvement within 48–72 hours. CRP should decline by >50% at day 3–4.
Treatment failure at 72 hours: Reassess: rule out complications (empyema, lung abscess), drug-resistant organism, atypical pathogen, non-infectious mimic (malignancy, TB, eosinophilic pneumonia). Obtain sputum culture. Consider broadening coverage (ceftriaxone + macrolide or respiratory fluoroquinolone). ⚠️ India-specific: Always consider tuberculosis in non-resolving pneumonia — obtain sputum for AFB smear and GeneXpert.
Baseline investigations: MANDATORY: Chest X-ray, SpO₂, allergy history. RECOMMENDED: CBC, CRP/procalcitonin, renal function (for cefuroxime dose adjustment if needed), blood cultures (if hospitalised), sputum Gram stain and culture.
Specialist initiation: Not required for non-severe outpatient CAP — primary care appropriate. Hospitalised CAP: physician/internist. ICU-level CAP: do NOT use cefuroxime.
Indian guideline source: API Textbook of Medicine (CAP chapter); ICMR Antimicrobial Treatment Guidelines 2019; Joint ICS-NCDC Guidelines for CAP. ℹ️ API Textbook lists cefuroxime as one of the parenteral beta-lactam options for hospitalised non-severe CAP alongside ampicillin-sulbactam and amoxicillin-clavulanate IV.
Key safety warning: ⚠️ Oral cefuroxime axetil must be taken WITH FOOD — if the patient reports taking it on an empty stomach, this may explain apparent treatment failure (subtherapeutic serum levels due to ~40–50% reduced absorption).
Dose adjustment: Renal impairment: extend interval per CrCl (see Part 3). Elderly: assess renal function. Obesity: standard doses generally adequate for non-severe CAP.

Indication 2: ACUTE OTITIS MEDIA (AOM) — Second-Line Therapy

Route	Per-Dose	Frequency	Duration
Oral (cefuroxime axetil)	250–500 mg	Every 12 hours WITH FOOD	5–10 days (5 days if ≥2 years with mild; 10 days if <2 years or severe)

⚠️ AOM is primarily a paediatric indication — adult AOM dosing is the same as above. See Paediatric Dosing section for weight-based paediatric dosing.

Mandatory Clinical Notes:

When to prefer cefuroxime for AOM:
- ✅ Second-line after amoxicillin failure (no improvement at 48–72 hours on first-line amoxicillin 80–90 mg/kg/day). IAP Guidelines and API Textbook recommend amoxicillin-clavulanate OR oral cefuroxime axetil as second-line for AOM.
- ✅ When amoxicillin is contraindicated (non-severe penicillin allergy — cefuroxime is a cephalosporin alternative with low cross-reactivity ~2–5%).
- ✅ When beta-lactamase-producing H. influenzae is suspected (recurrent AOM, daycare attendance, recent antibiotic exposure).
When NOT to use:
- ⛔ NOT first-line for uncomplicated AOM — first-line is high-dose amoxicillin (80–90 mg/kg/day) per IAP and AAP guidelines. Cefuroxime is second-line.
- ⛔ If compliance is a concern: cefuroxime axetil suspension has a notoriously bitter taste — poor palatability is a major barrier to paediatric adherence. If taste is an issue, cefpodoxime proxetil or cefdinir suspensions (better-tasting) may be preferred alternatives.
NLEM India: ✅ Injection is NLEM. Oral is NOT NLEM-listed (amoxicillin-clavulanate is NLEM for this indication).
Time to response: 48–72 hours. If no improvement → ENT referral, tympanocentesis for culture.
Indian guideline: IAP Guidelines on AOM; API Textbook.

Indication 3: ACUTE BACTERIAL SINUSITIS (ABS) — Second-Line Therapy

Route	Per-Dose	Frequency	Duration
Oral (cefuroxime axetil)	250–500 mg	Every 12 hours WITH FOOD	5–7 days (uncomplicated); 10–14 days (complicated/recurrent)

Mandatory Clinical Notes:

When to prefer: Second-line after amoxicillin or amoxicillin-clavulanate failure. Covers S. pneumoniae, H. influenzae (including beta-lactamase producers), M. catarrhalis — the three primary ABS pathogens.
When NOT to use: ⛔ NOT first-line — first-line is amoxicillin or amoxicillin-clavulanate per API Textbook and ICMR guidelines. ⛔ NOT for suspected fungal sinusitis, complicated sinusitis with intracranial extension, or nosocomial sinusitis (likely MDR organisms).
Diagnosis confirmation: Bacterial sinusitis requires: symptoms ≥10 days without improvement, OR worsening after initial improvement (“double sickening”), OR severe onset (high fever ≥39°C + purulent discharge ≥3 days). Do NOT prescribe cefuroxime for viral rhinosinusitis (the vast majority of cases).
NLEM India: ✅ Injection NLEM.
Indian guideline: API Textbook (ENT Infections chapter); ICMR Guidelines.

Indication 4: ACUTE EXACERBATION OF COPD (AECOPD) — Moderate Severity

Route	Per-Dose	Frequency	Duration
IV (hospitalised)	750 mg–1.5 g	Every 8 hours	Until improving → oral step-down. Total 5–7 days.
Oral step-down / Outpatient	500 mg cefuroxime axetil	Every 12 hours WITH FOOD	5–7 days total

Mandatory Clinical Notes:

When to prefer: AECOPD with at least 2 of 3 Anthonisen criteria (increased dyspnoea, increased sputum volume, increased sputum purulence) — especially if purulent sputum is present (strongest predictor of bacterial infection). Cefuroxime covers the three commonest AECOPD pathogens: H. influenzae, S. pneumoniae, M. catarrhalis. API Textbook and GOLD 2024 guidelines list cefuroxime as an appropriate oral/parenteral beta-lactam option.
When NOT to use: ⛔ NOT for mild AECOPD without purulent sputum (antibiotics unlikely to benefit). ⛔ NOT if Pseudomonas risk factors (frequent exacerbations, structural lung disease, recent hospitalisation, chronic systemic steroid use) — use antipseudomonal agent (piperacillin-tazobactam, cefepime). ⛔ NOT if ESBL gram-negative suspected.
NLEM India: ✅ Injection NLEM.
Indian guideline: API Textbook (COPD chapter); GOLD 2024.

Indication 5: URINARY TRACT INFECTIONS (UTI) — Complicated and Uncomplicated

5A: Uncomplicated Lower UTI (Acute Cystitis)

Route	Per-Dose	Frequency	Duration
Oral (cefuroxime axetil)	250 mg	Every 12 hours WITH FOOD	3–5 days

5B: Complicated UTI / Acute Pyelonephritis

Route	Per-Dose	Frequency	Duration
IV (hospitalised pyelonephritis/cUTI)	750 mg–1.5 g	Every 8 hours	Until afebrile ≥48 hrs → oral step-down. Total 10–14 days.
Oral step-down	500 mg cefuroxime axetil	Every 12 hours WITH FOOD	To complete total course

Mandatory Clinical Notes:

When to prefer cefuroxime for UTI:
- ✅ When urine culture confirms a susceptible, non-ESBL organism (E. coli, Proteus, Klebsiella — non-ESBL).
- ✅ As an alternative to amoxicillin-clavulanate when the latter is not tolerated (GI side effects).
- ⚠️ Cefuroxime is NOT first-line for uncomplicated cystitis. Preferred first-line per ICMR guidelines: nitrofurantoin 100 mg BD × 5 days or fosfomycin 3 g single dose.
⚠️ CRITICAL India-specific limitation — ESBL prevalence:
- ESBL prevalence among Indian uropathogens: 40–70% in hospital-acquired UTIs; 20–40% in community-acquired UTIs in urban India.
- Cefuroxime is COMPLETELY INEFFECTIVE against ESBL producers.
- ⚠️ Always obtain urine culture and sensitivity BEFORE starting cefuroxime for UTI — especially in India. If culture returns ESBL: switch immediately (nitrofurantoin for lower UTI; carbapenem or piperacillin-tazobactam for complicated/upper UTI).
NLEM India: ✅ Injection NLEM.
Baseline investigations: MANDATORY: Urine routine + culture-sensitivity before starting. Renal function (dose adjustment if CrCl <30).
Indian guideline: ICMR AMR Treatment Guidelines 2019; API Textbook.

Indication 6: SKIN AND SOFT TISSUE INFECTIONS (SSTIs) — Mild to Moderate

Route	Per-Dose	Frequency	Duration
IV (hospitalised, moderate SSTI)	750 mg	Every 8 hours	Until improving → oral step-down. Total 5–10 days.
Oral (outpatient, mild-moderate)	250–500 mg cefuroxime axetil	Every 12 hours WITH FOOD	5–10 days

Mandatory Clinical Notes:

When to prefer: Mild-moderate community-acquired SSTIs (cellulitis, wound infection, impetigo requiring systemic therapy) where both staphylococcal AND streptococcal coverage is needed but the infection is NOT severe enough for IV antistaphylococcal penicillin or cefazolin.
When NOT to use:
- ⛔ MRSA SSTI — cefuroxime is inactive. Use cotrimoxazole, doxycycline, clindamycin, or vancomycin.
- ⛔ Serious/deep MSSA infections (bacteraemia, endocarditis, osteomyelitis) — cefuroxime has LESS anti-MSSA potency than first-generation cephalosporins (cefazolin) or antistaphylococcal penicillins (cloxacillin). For serious MSSA infections: use cefazolin or cloxacillin.
- ⛔ Polymicrobial SSTIs (bite wounds, diabetic foot, perianal) — need anaerobic coverage (add metronidazole or use amoxicillin-clavulanate/ampicillin-sulbactam).
- ⛔ Necrotising fasciitis — surgical emergency + broad-spectrum IV antibiotics.
NLEM India: ✅ Injection NLEM.
Indian guideline: API Textbook; ICMR AMR Guidelines; IADVL Guidelines.

Indication 7: SURGICAL PROPHYLAXIS — Select Procedures

Route	Per-Dose	Timing	Re-dosing	Post-Op Duration
IV	1.5 g	30–60 minutes before incision (at induction of anaesthesia)	Re-dose at 3–4 hours intraoperatively (based on ~1.5-hour half-life — re-dose at ~2× half-life). Re-dose if blood loss >1500 mL.	⛔ Single dose preferred. Maximum 24 hours post-operatively.

Procedures where cefuroxime prophylaxis is used in India:

Procedure Type	Standard Protocol	Notes
Orthopaedic surgery (joint replacement, ORIF, spine)	1.5 g IV pre-op + re-dose q3–4h intra-op + up to 24 hrs post-op	ℹ️ Cefazolin is generally PREFERRED over cefuroxime for orthopaedic prophylaxis in most Indian and international guidelines — superior MSSA coverage, longer half-life (q4h re-dosing vs q3–4h). However, cefuroxime is an acceptable alternative (AIIMS orthopaedic protocol includes both). UK NICE guidelines specifically recommend cefuroxime for orthopaedic prophylaxis.
Cardiac surgery (CABG, valve)	1.5 g IV pre-op + q8h × 24–48 hrs post-op	Cefazolin preferred by most Indian cardiac centres; cefuroxime is an acceptable alternative per some protocols (AIIMS cardiac surgery protocol).
Abdominal / Colorectal surgery	1.5 g IV pre-op + Metronidazole 500 mg IV	⚠️ Cefuroxime alone is INSUFFICIENT for colorectal procedures — no anaerobic (B. fragilis) coverage. Must add metronidazole. Some protocols prefer cefazolin + metronidazole or ampicillin-sulbactam as single-agent alternatives.
Head and neck surgery (involving mucosal incision)	1.5 g IV pre-op + metronidazole for anaerobic cover
Gynaecological surgery (hysterectomy, C-section)	1.5 g IV pre-op	Cefazolin is preferred for C-section prophylaxis per FOGSI/ACOG. Cefuroxime is an alternative.
Neurosurgery (craniotomy, VP shunt)	1.5 g IV pre-op	Some UK-based protocols prefer cefuroxime for neurosurgical prophylaxis (better gram-negative coverage than cefazolin including H. influenzae). Indian practice varies.

Mandatory Clinical Notes (Surgical Prophylaxis):

Cefazolin vs Cefuroxime for surgical prophylaxis — which to choose?
- Cefazolin is the globally preferred first-line prophylactic agent for most clean and clean-contaminated surgeries: longer half-life (q4h re-dosing vs q3–4h for cefuroxime), superior MSSA coverage, better-established weight-based dosing (2 g standard; 3 g for ≥120 kg), NLEM-listed, and most Indian surgical prophylaxis protocols list cefazolin as first-line.
- Cefuroxime is a valid alternative — particularly favoured in some UK-influenced protocols (NICE). Its advantage: slightly broader gram-negative coverage (especially H. influenzae) which may be marginally beneficial for procedures involving mucosal surfaces (head & neck, ENT, dental) where H. influenzae colonisation is relevant.
- In Indian practice: Most Indian surgical prophylaxis protocols (AIIMS, NCDC) list cefazolin as first-line with cefuroxime as an acceptable alternative. Either is reasonable.
⚠️ Re-dosing interval is SHORTER for cefuroxime than cefazolin: Cefuroxime half-life (~1.5 hrs) < cefazolin half-life (~2 hrs) → re-dose at 3–4 hours intraoperatively (vs q4h for cefazolin). Failure to re-dose in long procedures is a common prophylaxis failure.
⛔ Do NOT continue prophylaxis >24 hours — same antimicrobial stewardship principle as cefazolin.
NLEM India: ✅ Cefuroxime injection (750 mg, 1.5 g) IS NLEM-listed.
Indian guideline: AIIMS Surgical Prophylaxis Protocol; NCDC Infection Control Guidelines; ASHP/IDSA/SIS Surgical Prophylaxis Guidelines 2013 (adapted for Indian practice).

Indication 8: EARLY LYME DISEASE (Erythema Migrans) — Oral Therapy

Route	Per-Dose	Frequency	Duration
Oral (cefuroxime axetil)	500 mg	Every 12 hours WITH FOOD	14–21 days

Mandatory Clinical Notes:

Context for Indian practice: Lyme disease (caused by Borrelia burgdorferi sensu lato) is uncommon in India but has been reported in forested/hilly regions — Himalayan states (Himachal Pradesh, Uttarakhand, Jammu & Kashmir), northeast India (Assam, Meghalaya, Manipur), and parts of Western Ghats. Indian clinicians in these regions should be aware of Lyme disease in patients with tick exposure + erythema migrans rash.
Drug of choice: First-line for early Lyme disease (erythema migrans without neurological or cardiac involvement): Doxycycline 100 mg oral BD × 14–21 days (also covers co-infections; contraindicated in children <8 years and pregnancy). Cefuroxime axetil and amoxicillin are alternatives — particularly when doxycycline is contraindicated (children <8 years, pregnancy).
NLEM India: ✅ Injection NLEM. Not specifically listed for Lyme indication (disease is rare in India).
Indian guideline: Limited Indian Lyme disease guidelines. API Textbook mentions Lyme disease. IDSA/AAN/ACR Lyme Disease Guidelines 2020 used internationally.

Secondary Indications — Adults Only (Off-label, if any)

Off-Label Indication 1: INTRACAMERAL CEFUROXIME — Endophthalmitis Prophylaxis After Cataract Surgery

Status: OFF-LABEL but accepted standard practice internationally and increasingly in Indian ophthalmology. ⚠️ Specialist ophthalmology use only.

Route	Dose	Timing	Duration
Intracameral (injection into the anterior chamber of the eye at the end of cataract surgery)	1 mg in 0.1 mL (prepared by diluting cefuroxime sodium injection to a concentration of 10 mg/mL using balanced salt solution — BSS)	Single injection at the conclusion of cataract surgery (after IOL implantation, before wound closure)	Single dose — one-time administration

Clinical Notes:

💡 This is one of the most impactful antimicrobial prophylaxis interventions in modern ophthalmology. The landmark ESCRS Endophthalmitis Study (Barry et al., J Cataract Refract Surg, 2006; European multicentre RCT, n=16,603) demonstrated that intracameral cefuroxime reduced post-cataract endophthalmitis rates by approximately 5-fold (from ~0.35% to ~0.07%) compared to no intracameral injection.
⚠️ Preparation is CRITICAL — dilution errors can cause retinal toxicity. The standard cefuroxime sodium injection vial (750 mg or 1.5 g) must be diluted meticulously to achieve the final concentration of 10 mg/mL, from which 0.1 mL is drawn (= 1 mg). Overdosing (>1 mg) can cause toxic anterior segment syndrome (TASS) or macular oedema. Underdosing provides no prophylaxis. Many Indian ophthalmology centres now use pre-diluted, pharmacy-prepared aliquots or commercially available intracameral cefuroxime preparations (e.g., Aprokam — available in some international markets; availability in India may be limited — most centres prepare from standard IV vials under aseptic conditions).
⚠️ Specialist only — ophthalmologist administration in a sterile OT environment. NOT for general prescribing.
ℹ️ India-specific: Cataract surgery is the most commonly performed surgical procedure in India (millions of procedures annually through government and private programmes). Post-operative endophthalmitis, though rare (~0.04–0.2%), is a devastating complication causing blindness. Adoption of intracameral cefuroxime prophylaxis in Indian ophthalmology is increasing but not yet universal. Barriers include: concern about dilution errors, cost, perceived medicolegal risk of off-label use, and availability of pre-prepared formulations. AIOS (All India Ophthalmological Society) has endorsed intracameral cefuroxime prophylaxis.
Evidence basis: Strong — ESCRS RCT (2006); multiple confirmatory observational studies and meta-analyses; ESCRS Guidelines for Prevention of Endophthalmitis After Cataract Surgery (2013); AIOS endorsement.

Dilution Protocol (Reference — For Ophthalmology OT Staff):

Step	Action	Result
1	Reconstitute 750 mg cefuroxime sodium vial with 7.5 mL SWFI	Concentration = 100 mg/mL
2	Draw 1 mL of this solution	Contains 100 mg cefuroxime
3	Add this 1 mL to 9 mL of BSS (Balanced Salt Solution)	Concentration = 10 mg/mL
4	Draw 0.1 mL from this diluted solution	Contains 1 mg cefuroxime — this is the intracameral dose

⚠️ Use a 1 mL tuberculin syringe with 0.01 mL graduations for step 4 to ensure accuracy. Prepare fresh for each patient. Discard any unused diluted solution (no preservative).

Off-Label Indication 2: GONORRHOEA — NO LONGER RECOMMENDED

Status: ⛔ Previously used but NOW OBSOLETE — gonococcal resistance to cefuroxime has risen to unacceptable levels in India and globally.

ℹ️ Historical note: Oral cefuroxime axetil 1 g single dose was previously used for uncomplicated gonorrhoea. This is NO LONGER recommended due to widespread resistance. Current Indian (NACO/ICMR) and international (WHO) guidelines recommend Ceftriaxone 500 mg IM single dose (or 250 mg IM in some guidelines) + azithromycin 1 g oral single dose (dual therapy) as first-line for gonorrhoea. Do NOT use cefuroxime for gonorrhoea in current practice.

Off-Label Indication 3: PERIOPERATIVE PROPHYLAXIS — Intracameral (Eye Surgery) + Topical Drops

Status: OFF-LABEL — see Off-Label Indication 1 above for intracameral use. Some ophthalmologists also use cefuroxime sodium as fortified topical eye drops (compounded preparation, 50 mg/mL) for treatment of bacterial keratitis or as prophylaxis — this is a compounded, off-label practice.

PAEDIATRIC DOSING (Specialist Only)

General Notes — Paediatric

Safety monitoring: Monitor for allergic reactions (rash, urticaria, anaphylaxis — rare), diarrhoea (common with oral cefuroxime axetil), and GI intolerance (nausea, vomiting — common). Renal function monitoring if prolonged course or concurrent nephrotoxic drugs.
Minimum age: No specific lower age limit — used from the neonatal period onwards under specialist supervision (see neonatal section). Commonly prescribed from ≥3 months of age for standard paediatric indications.
Formulation suitability:
- Oral suspension (cefuroxime axetil 125 mg/5 mL): Available but with a MAJOR palatability problem. ⚠️ Cefuroxime axetil suspension has one of the WORST tastes among commonly prescribed paediatric oral antibiotics — intensely bitter, difficult to mask even with flavouring. This is a well-recognised barrier to paediatric compliance. Many Indian paediatricians avoid cefuroxime suspension specifically because of taste issues, preferring cefpodoxime proxetil or cefixime suspension (both better-tasting) for paediatric use.
- Tablets (125 mg, 250 mg, 500 mg): Film-coated — suitable for older children who can swallow tablets whole. ⛔ Do NOT crush (extremely bitter + may reduce bioavailability).
- IV/IM injection: Reconstituted from vials for weight-based paediatric dosing.
Palatability — THE major paediatric prescribing issue:
- If taste is a barrier and the child refuses cefuroxime suspension: switch to amoxicillin-clavulanate (better taste, similar spectrum), cefpodoxime proxetil (palatable suspension, similar respiratory coverage), or cefixime (palatable, good gram-negative coverage but weaker gram-positive).
- Practical tips: mix the measured dose with a small amount of chocolate syrup or honey (for children >1 year) immediately before administration. DO NOT mix into a bottle of milk/formula (if child doesn’t finish, dose is incomplete).
Age-specific PK: Neonates: prolonged half-life (~3–5 hours) — extended intervals. Infants >3 months: standard weight-based dosing adequate.
Adolescent transition: Children ≥12 years or ≥40 kg → use adult dosing.

⚠️ All oral paediatric doses of cefuroxime axetil must be given WITH FOOD.

PAEDIATRIC DOSING REFERENCE TABLE

PARENTERAL (Cefuroxime Sodium):

Dosing Tier	Dose	Frequency	Typical Use
Standard	20–30 mg/kg/dose	Every 8 hours (q8h)	Most moderate infections
Severe	50 mg/kg/dose	Every 6–8 hours (q6–8h)	Severe infections, bacteraemia
Maximum	50 mg/kg/dose (max 1.5 g per dose; max 6 g/day)	q6–8h	Life-threatening infections
Surgical prophylaxis	30 mg/kg (max 1.5 g)	Single pre-op dose ± intraoperative re-dosing	Paediatric surgical prophylaxis

ORAL (Cefuroxime Axetil — WITH FOOD):

Dosing Tier	Dose	Frequency	Typical Use
Standard (most infections)	10–15 mg/kg/dose (max 250 mg per dose)	Every 12 hours (q12h)	AOM, sinusitis, mild SSTI, UTI
Higher dose (AOM second-line)	15 mg/kg/dose (max 500 mg per dose)	Every 12 hours (q12h)	Recurrent/refractory AOM, moderate infections
Maximum oral	500 mg per dose; 1 g per day	q12h	—

Primary Indications — Paediatric (Approved / Standard in India)

Paediatric Indication 1: ACUTE OTITIS MEDIA (AOM) — Second-Line

Route	Dose	Frequency	Duration
Oral (cefuroxime axetil — WITH FOOD)	15 mg/kg/dose (max 500 mg per dose)	Every 12 hours	5 days (≥2 years, mild); 10 days (<2 years or severe/recurrent)

Clinical Notes:

⚠️ NOT first-line. First-line for AOM: high-dose amoxicillin (80–90 mg/kg/day divided q8–12h) per IAP Guidelines and API Textbook.
Cefuroxime is second-line for: (a) amoxicillin failure at 48–72 hours; (b) amoxicillin allergy (non-severe penicillin allergy); © recurrent AOM with suspected beta-lactamase-producing H. influenzae.
⚠️ Palatability barrier: Cefuroxime axetil suspension is very bitter. If child refuses: switch to amoxicillin-clavulanate (preferred second-line per IAP) or cefpodoxime proxetil suspension (better taste).
IAP Guidelines on AOM; API Textbook.
NLEM: ✅ (injection).

Paediatric Indication 2: ACUTE BACTERIAL SINUSITIS — Second-Line

Route	Dose	Frequency	Duration
Oral (cefuroxime axetil — WITH FOOD)	15 mg/kg/dose (max 500 mg)	Every 12 hours	10–14 days

Clinical Notes:

Second-line after amoxicillin/amoxicillin-clavulanate failure.
Same palatability concerns as AOM.
Same first-line preferences (amoxicillin-clavulanate per IAP/API).

Paediatric Indication 3: COMMUNITY-ACQUIRED PNEUMONIA — Paediatric, Hospitalised

Route	Dose	Frequency	Duration
IV (hospitalised, non-severe)	25–50 mg/kg/dose	Every 8 hours	Until improving → oral step-down. Total 5–7 days.
Oral step-down / Outpatient	15 mg/kg/dose (max 500 mg) cefuroxime axetil WITH FOOD	Every 12 hours	To complete total 5–7 days

Clinical Notes:

ℹ️ For hospitalised paediatric CAP, first-line per IAP and WHO is IV ampicillin (or IV benzylpenicillin for confirmed pneumococcal pneumonia). Cefuroxime is used when: broader gram-negative coverage needed (H. influenzae), first-line failure, or non-severe penicillin allergy.
Combine with macrolide (azithromycin 10 mg/kg/day OD × 5 days) if atypical pneumonia suspected (children >5 years).
⚠️ India-specific: Always consider TB in non-resolving paediatric pneumonia.
IAP Guidelines on Paediatric Pneumonia; WHO Pneumonia Guidelines.
NLEM: ✅ (injection).

Paediatric Indication 4: URINARY TRACT INFECTIONS — Paediatric

Route	Dose	Frequency	Duration
IV (severe pyelonephritis/cUTI)	25–50 mg/kg/dose	Every 8 hours	Until afebrile ≥48 hrs → oral step-down. Total 10–14 days.
Oral (mild-moderate cystitis/step-down)	10–15 mg/kg/dose (max 250 mg) cefuroxime axetil WITH FOOD	Every 12 hours	3–5 days (cystitis); to complete 10–14 days (pyelonephritis step-down)

Clinical Notes:

Obtain urine C&S before starting — MANDATORY.
⚠️ ESBL prevalence in paediatric uropathogens rising in India — cefuroxime may be unreliable empirically.
All children with first febrile UTI: renal ultrasound recommended. DMSA/MCU per IAP Paediatric Nephrology guidelines.
NLEM: ✅ (injection).
IAP Guidelines for UTI in Children.

Paediatric Indication 5: SKIN AND SOFT TISSUE INFECTIONS — Paediatric, Mild-Moderate

Route	Dose	Frequency	Duration
Oral (cefuroxime axetil — WITH FOOD)	10–15 mg/kg/dose (max 250–500 mg)	Every 12 hours	5–7 days
IV (moderate-severe, hospitalised)	25–50 mg/kg/dose	Every 8 hours	Until improving → oral step-down

Clinical Notes:

For community-acquired paediatric SSTI (cellulitis, impetigo requiring systemic therapy).
⛔ NOT for MRSA SSTI (use cotrimoxazole or clindamycin).
⛔ NOT for bite wounds as monotherapy (add metronidazole for anaerobic coverage or use amoxicillin-clavulanate).
Oral step-down to cefuroxime axetil or cephalexin (better taste for children).
NLEM: ✅ (injection).

Paediatric Indication 6: SURGICAL PROPHYLAXIS — Paediatric

Route	Dose	Timing	Re-dosing	Post-Op
IV	30 mg/kg (max 1.5 g)	Within 60 minutes before incision	Re-dose if procedure >3–4 hours or blood loss >25 mL/kg	⛔ Single dose preferred. Maximum 24 hours.

Clinical Notes:

Same principles as adult prophylaxis. Cefazolin is generally preferred; cefuroxime is an acceptable alternative.
For paediatric colorectal/GI procedures: add metronidazole 7.5 mg/kg IV.
IAP Guidelines; AIIMS Paediatric Surgery Protocol.
NLEM: ✅ (injection).

Neonatal Dosing

⚠️ Neonatal use — NICU supervision only.

ℹ️ Cefuroxime half-life is prolonged in neonates (~3–5 hours) due to immature renal function — extended dosing intervals required.

Age / Gestational Age	Per-Dose	Frequency	Notes
Preterm (<37 weeks GA), ≤7 days	25 mg/kg/dose IV	Every 12 hours (q12h)	NICU supervision only.
Term (≥37 weeks GA), ≤7 days	25 mg/kg/dose IV	Every 8–12 hours (q8–12h)	NICU supervision.
Term, 8–28 days	25 mg/kg/dose IV	Every 8 hours (q8h)	Renal function maturing.

Critical Neonatal Notes:

⛔ Cefuroxime is NOT first-line for empiric neonatal sepsis. Standard empiric EONS therapy per NNF India / AIIMS: Ampicillin + Gentamicin. Cefuroxime has NO activity against Listeria monocytogenes (all cephalosporins are intrinsically resistant to Listeria) or Enterococcus — both important EONS pathogens.
When cefuroxime IS used in neonates:
- Targeted therapy for culture-confirmed susceptible gram-negative organisms (after initial empiric regimen)
- Surgical prophylaxis for neonatal surgery (cardiac, abdominal)
- NOT as empiric first-line
⛔ No oral formulation suitable for neonates. IV cefuroxime throughout neonatal treatment course. Oral step-down only post-neonatal period with cephalexin or cefuroxime axetil suspension.

Secondary Indications — Paediatric (Off-label, if any)

Off-Label Paediatric Indication 1: EARLY LYME DISEASE — Children

Status: OFF-LABEL (Lyme disease is rare in India)

Route	Dose	Frequency	Duration
Oral (cefuroxime axetil — WITH FOOD)	15 mg/kg/dose (max 500 mg)	Every 12 hours	14–21 days

Clinical Notes:

For children <8 years (where doxycycline is contraindicated) with early Lyme disease (erythema migrans).
Alternative: amoxicillin 50 mg/kg/day divided q8h × 14–21 days (preferred by many paediatricians due to better taste and bioavailability).
⚠️ Palatability: cefuroxime axetil suspension is very bitter — may be difficult for young children.
Evidence basis: Moderate — IDSA/AAN/ACR Lyme Disease Guidelines 2020 list cefuroxime as a recommended alternative oral agent for early Lyme. Limited paediatric RCTs.
Relevance in India: limited to Himalayan and northeast states.

Off-Label Paediatric Indication 2: PHARYNGOTONSILLITIS (GAS) — Alternative in Penicillin Allergy

Status: OFF-LABEL (first-line for GAS pharyngitis is penicillin V or amoxicillin)

Route	Dose	Frequency	Duration
Oral (cefuroxime axetil — WITH FOOD)	10 mg/kg/dose (max 250 mg)	Every 12 hours	10 days (to ensure GAS eradication and prevent rheumatic fever)

Clinical Notes:

ℹ️ First-line for GAS pharyngitis: Penicillin V (250 mg BD–TDS × 10 days for children ≥12 years; 125–250 mg BD–TDS for younger children) or Amoxicillin (50 mg/kg/day divided BD–TDS × 10 days). Cefuroxime is an alternative for non-severe penicillin allergy.
⚠️ India-specific — Rheumatic fever prevention: India has one of the world’s highest burdens of rheumatic heart disease (RHD). Complete 10-day GAS pharyngitis treatment is CRITICAL for primary prevention of acute rheumatic fever. Shorter courses with any antibiotic are NOT acceptable for GAS pharyngitis in the Indian context — the prevention of rheumatic fever mandates full 10-day eradication therapy.
Evidence basis: Strong — Multiple RCTs support cephalosporins (including cefuroxime) for GAS pharyngitis. AHA/IDSA Pharyngitis Guidelines; IAP Guidelines.

Off-Label Paediatric Indication 3: PERIORBITAL (PRESEPTAL) CELLULITIS — Mild-Moderate

Status: OFF-LABEL (most guidelines recommend amoxicillin-clavulanate or ampicillin-sulbactam as first-line for empiric preseptal cellulitis coverage)

Route	Dose	Frequency	Duration
IV (moderate — hospitalised)	25–50 mg/kg/dose	Every 8 hours	Until improving → oral step-down. Total 7–10 days.
Oral (mild — outpatient)	15 mg/kg/dose (max 500 mg) cefuroxime axetil WITH FOOD	Every 12 hours	7–10 days

Clinical Notes:

Cefuroxime provides coverage against S. aureus (MSSA), Streptococcus spp., AND H. influenzae — the three main preseptal cellulitis pathogens.
⚠️ CRITICAL: Differentiate preseptal from orbital cellulitis. Orbital cellulitis: proptosis, EOM restriction, visual changes → CT orbit + broader IV coverage + ophthalmology + ENT referral.
Amoxicillin-clavulanate or ampicillin-sulbactam are more commonly used empirically (also cover anaerobes from sinusitis extension).
Evidence basis: Weak — expert opinion, case series.

Paediatric Secondary Indications Summary Table

#	Indication	Route	Evidence	Specialist Required
1	Early Lyme disease (<8 years — doxycycline contraindicated)	Oral	Moderate	Paediatrician
2	GAS pharyngotonsillitis — penicillin allergy alternative	Oral	Strong	Paediatrician (primary care appropriate)
3	Periorbital cellulitis — mild-moderate	IV/Oral	Weak	Paediatrician/Ophthalmologist

MISSED DOSE / DELAYED DOSE GUIDANCE

ℹ️ Cefuroxime is available as both parenteral (IV/IM — hospital setting) and oral (cefuroxime axetil — outpatient setting) formulations. Missed dose guidance differs by route and clinical context.

Cefuroxime is a time-dependent bactericidal antibiotic — efficacy depends on maintaining free drug concentrations above the MIC for the maximum percentage of the dosing interval (%fT > MIC). The half-life (~1–2 hours) and high free drug fraction (~50–67%) mean that at standard dosing (IV q8h or oral q12h), adequate bactericidal activity is maintained through most of the dosing interval — but significant delays or missed doses create subtherapeutic windows.

For Parenteral (IV/IM) — q8h Dosing (Hospital Setting)

Doses administered by nursing staff on a fixed q8h schedule (e.g., 06:00, 14:00, 22:00).
If delayed <4 hours: Administer immediately. Re-space subsequent doses to maintain q8h intervals from the delayed dose.
If delayed >4 hours: Administer immediately. Inform treating physician. Resume regular q8h schedule from the delayed dose timing.
⚠️ For critically ill patients or those with serious infections (bacteraemia, severe pneumonia): If delay exceeds 2 hours, inform the treating physician — even a 2-hour gap with cefuroxime’s ~1.5-hour half-life means serum levels may have fallen to near-subtherapeutic.
Never skip a dose entirely without physician instruction.

For Parenteral — q6h Dosing (Maximum/Severe Infections)

If delayed <3 hours: Administer immediately. Re-space.
If delayed >3 hours: Administer immediately, inform physician, resume schedule from delayed dose.

For Oral (Cefuroxime Axetil) — q12h Dosing (Outpatient)

If remembered within 6 hours of the scheduled time: Take the missed dose immediately WITH FOOD. Then resume regular q12h schedule.
If more than 6 hours late (i.e., next dose due within 6 hours): Skip the missed dose. Take the next dose at its scheduled time WITH FOOD. Do NOT double the dose.
Never take two doses at once.

💡 Practical timing guidance for oral cefuroxime q12h:

Suggested schedule linked to meals: Morning dose with breakfast; Evening dose with dinner — leverages the mandatory “take with food” instruction to create a natural dosing anchor tied to meal times.
This meal-linked schedule is easy for patients to remember and ensures both the q12h interval AND the food requirement are met simultaneously.

For Surgical Prophylaxis

Pre-operative dose missed: If recognised before incision → give immediately (even if within <30 minutes of incision — some tissue levels are better than none). If recognised after incision → give ASAP — late prophylaxis provides some benefit though suboptimal. Document the timing error.
Intraoperative re-dosing missed: If the procedure exceeded 3–4 hours and re-dosing was not given → administer immediately upon recognition. If only recognised at the end of surgery → give as a post-operative dose.

Prolonged Non-Adherence / Drug Holiday Guidance

Cefuroxime is used as a finite-duration antibiotic course (typically 5–14 days). Not chronic therapy.
If 2 or more consecutive oral doses are missed:
- Sub-therapeutic levels will have been present for ≥24 hours → bacterial regrowth risk.
- Resume immediately at full dose WITH FOOD — no re-titration needed.
- Extend total course duration by the number of missed days.
- If treating a serious infection (pyelonephritis, pneumonia) and multiple doses missed → reassess clinically, consider repeat cultures, and evaluate whether the missed doses have compromised treatment response.
No withdrawal syndrome or rebound effect.
No immunogenicity risk (not a biologic).

Counselling Point for Patients (Oral Cefuroxime)

“Take this medicine twice a day with food — morning with breakfast and evening with dinner. If you forget a dose, take it as soon as you remember WITH FOOD — unless your next dose is due in less than 6 hours. In that case, skip the missed dose and take the next one on time. NEVER take two doses together. Always take this medicine with food — it works much better when taken with a meal.”

RECONSTITUTION / ADMINISTRATION QUICK REFERENCE (For Nurses & Clinical Staff)

A. INTRAVENOUS ADMINISTRATION — Cefuroxime Sodium

Reconstitution of IV Vials

Parameter	750 mg Vial	1.5 g Vial
Diluent for reconstitution	Sterile Water for Injection (SWFI) — preferred. Normal Saline (NS) also acceptable.	Same
Volume of diluent	At least 6 mL (yields ~6.6 mL total volume)	At least 15 mL (to ensure complete dissolution)
Approximate final concentration	~113 mg/mL	~100 mg/mL
Appearance	Clear to light yellow/amber solution. ⛔ Discard if deeply coloured (dark brown), cloudy, or precipitated.	Same

ℹ️ Dissolution note: Cefuroxime sodium powder can be slow to dissolve — it may take 1–2 minutes of vigorous shaking to achieve complete dissolution. Unlike some other cephalosporins (cefazolin — dissolves in seconds), cefuroxime requires patience during reconstitution. Incomplete dissolution → undissolved particles → potential for injection-site pain (IM) or vein irritation (IV).

💡 Practical tip for Indian hospital settings: If the powder does not dissolve completely after 2 minutes of shaking: warm the vial briefly by holding it in the palm of the hand for 30 seconds, then shake again. Do NOT use a microwave or autoclave to warm.

Further Dilution for IV Infusion

Parameter	Details
Compatible IV fluids	✅ Normal Saline (0.9% NaCl) — preferred (best stability). ✅ Dextrose 5% (D5W) — compatible. ✅ Ringer’s Lactate (RL) — compatible. ✅ Dextrose-Saline (DNS) — compatible.
Recommended dilution volume	50–100 mL for intermittent infusion (adults). 10–25 mL for paediatric/neonatal use.
Final concentration range	7.5–30 mg/mL (depending on dilution volume)
Incompatible solutions	⛔ Aminoglycosides — physical + chemical incompatibility. ⛔ Sodium bicarbonate — degradation at alkaline pH. ⛔ Do NOT add to TPN, blood products, or lipid emulsions.

Rate of Administration

Method	Rate	Notes
Slow IV Injection (Bolus/Push)	Over 3–5 minutes	For doses ≤750 mg, direct IV push over 3–5 minutes is acceptable and convenient.
Intermittent IV Infusion	Over 15–30 minutes	PREFERRED method for 1.5 g doses and for all treatment doses (reduces vein irritation). Dilute in 50–100 mL compatible fluid.
Infusion pump	Recommended for: paediatric/neonatal dosing, ICU patients, continuous infusion strategies.	Ensures accurate delivery.

Stability After Reconstitution

Condition	In SWFI	In NS	In D5W
Room temperature (25°C)	5 hours	24 hours	24 hours
Refrigerated (2–8°C)	48 hours	48 hours	24 hours
Protected from light?	Not mandatory — cefuroxime is not significantly photosensitive.	Same	Same
Freezing	⛔ Do NOT freeze reconstituted solutions prepared from dry powder.	—	—

⚠️ Stability note — SHORTER than cefazolin: Cefuroxime reconstituted stability (5–24 hours at RT, 24–48 hours refrigerated) is significantly shorter than cefazolin (24 hours at RT, 10 days refrigerated). This has practical implications:

Batch pre-preparation of cefuroxime doses is less feasible than with cefazolin
For OPAT: pre-prepared cefuroxime syringes/mini-bags have a shorter usable window than cefazolin — limiting home-based IV therapy logistics
In Indian hospitals: reconstitute immediately before each dose is the safest practice, especially in hot climates where room temperature stability may be reduced

💡 Indian hot-climate caveat: In Indian summer (ambient 35–45°C), room temperature stability will be shorter than 5–24 hours stated above (stability data based on 25°C). If ambient temperature exceeds 30°C: use reconstituted solution within 4 hours of preparation. If using NS as diluent (24-hour stability at 25°C): reduce to 8–12 hours in ambient temperatures >30°C. Refrigerate if any delay before use.

Multi-Dose Vial Handling

Cefuroxime vials are typically single-use (no preservative).
⛔ Do NOT re-puncture repeatedly — contamination risk.
For paediatric use where multiple small doses are drawn from one vial: use within the stated stability window, document reconstitution time, strict aseptic technique.
In neonatal settings: use single-dose vials (preservative-free) only.

Weight-Based Dosing Calculation Example (Paediatric IV)

Example: A 15 kg child prescribed cefuroxime 30 mg/kg/dose IV q8h:

Dose = 30 mg/kg × 15 kg = 450 mg per dose
Using 750 mg vial reconstituted in 6 mL SWFI → concentration ~113 mg/mL
Volume to draw = 450 mg ÷ 113 mg/mL = ~4 mL
Dilute in 25–50 mL Normal Saline; infuse over 15–30 minutes.
Or: administer 4 mL as slow IV push over 3–5 minutes.

Example (neonatal): A 3 kg term neonate (day 5 of life) prescribed cefuroxime 25 mg/kg/dose IV q8h:

Dose = 25 mg/kg × 3 kg = 75 mg per dose
Using 750 mg vial reconstituted in 6 mL → ~113 mg/mL
Volume to draw = 75 mg ÷ 113 mg/mL = ~0.66 mL
Dilute in 5–10 mL Normal Saline; infuse over 15–30 minutes using syringe pump.
⚠️ Use a 1 mL syringe for neonatal dosing accuracy.

Y-site / Line Compatibility

Compatible (Y-site)	Incompatible (Do NOT mix)
✅ Normal Saline, Dextrose 5%, Ringer’s Lactate, DNS	⛔ Aminoglycosides (gentamicin, amikacin, tobramycin) — NEVER mix. Flush with ≥20 mL NS between drugs. Use separate IV lines if both prescribed.
✅ Heparin (at Y-site — check local data)	⛔ Sodium bicarbonate — alkaline pH degrades cefuroxime
✅ Metronidazole — generally compatible (flush between)	⛔ Vancomycin — physical incompatibility reported; flush between
✅ Morphine, fentanyl (Y-site — institutional data)	⛔ Blood products, TPN, lipid emulsions
	⛔ Ciprofloxacin IV — reported incompatibility
	⛔ Clarithromycin IV — incompatible

Special Administration Notes

Topic	Details
Phlebitis	Moderate risk (~5–10%) — higher than cefazolin (~1–5%) but lower than nafcillin (~10–30%). Dilute adequately (≥50 mL for infusion), infuse over ≥15 minutes, rotate IV sites every 48–72 hours. For courses >5–7 days: consider PICC/midline.
Extravasation	Low risk — cefuroxime is NOT a vesicant. If extravasation occurs: mild local irritation. Apply warm compress. No specific antidote needed.
Flush line	Flush with 10–20 mL NS before and after, especially when aminoglycosides or vancomycin are co-infused.
Filter	Standard IV set — no special in-line filter required.
Colour change	Solution may darken slightly from pale yellow to deeper yellow on standing — this is normal within stability window. ⛔ Discard if dark amber/brown or precipitated.

B. INTRAMUSCULAR ADMINISTRATION — Cefuroxime Sodium

Parameter	Details
Reconstitution for IM	Reconstitute with Sterile Water for Injection (SWFI). 750 mg vial: add 3 mL → ~250 mg/mL (concentrated for IM volume).
IM injection site	Deep gluteal muscle (upper outer quadrant) in adults. Vastus lateralis (anterolateral thigh) in children <2 years. Deltoid: acceptable for adults if volume ≤2 mL.
Maximum IM volume per site	Adults: ≤3–5 mL per site. Children: ≤2 mL per site. Split dose between two sites if needed.
Pain at injection site	⚠️ Moderate-to-significant pain. IM cefuroxime is MORE painful than many other IM cephalosporins/penicillins due to the slower dissolution of the powder and the inherent irritancy of the solution. Reconstitution with 0.5% Lidocaine (Lignocaine) solution is recommended to reduce pain — standard practice. ⛔ Do NOT use lidocaine-reconstituted solution for IV administration. Some practitioners add 1% lidocaine to the IM reconstitution (0.75 mL of 2% lidocaine + 2.25 mL SWFI = ~0.5% solution in 3 mL).
IM absorption	Good (~90–95% bioavailability). Tmax ~45 minutes. Adequate for most moderate infections when IV access is unavailable.

C. ORAL ADMINISTRATION — Cefuroxime Axetil

Topic	Details
Administration	Tablets: Swallow WHOLE with water — ⛔ do NOT crush, chew, or split. Film coating masks extreme bitterness and protects the ester bond. Crushing → intensely bitter taste → vomiting/refusal (especially children) + potentially reduced bioavailability.
⚠️ TAKE WITH FOOD	CRITICAL INSTRUCTION — THE single most important counselling point for oral cefuroxime. Food increases oral bioavailability by ~40–50% (from ~37% to ~52%). Taking on empty stomach results in subtherapeutic serum levels → potential treatment failure. Write “TAKE WITH FOOD” prominently on every prescription.
Oral suspension	Shake well before each dose. Use measuring cup/oral syringe provided. ⚠️ Intensely bitter taste even with flavouring — major paediatric compliance barrier. Practical tips: (a) give immediately after mixing with a small amount of chocolate syrup or honey (>1 year old); (b) follow immediately with juice or flavoured drink; © do NOT mix into a full bottle of milk (incomplete dose if child doesn’t finish). If child still refuses: switch to better-tasting alternative (amoxicillin-clavulanate, cefpodoxime, or cefixime suspension).
Enteral tube (NG/PEG)	⛔ Tablets should NOT be crushed for tube administration (extremely bitter, potential bioavailability change). If enteral tube administration is needed: use the oral suspension formulation — can be administered via NG/PEG tube. Flush tube with 10–15 mL water before and after. However, if the patient is on enteral feeds, timing the suspension dose WITH the feed (as food increases absorption) may be practical. If enteral cefuroxime is impractical: switch to IV cefuroxime (same molecule — seamless transition).
Stability of oral suspension after reconstitution	10 days at room temperature (≤25°C) or 10 days refrigerated (2–8°C). Discard unused portion after 10 days. In Indian summer (>30°C): refrigerate and use within 7 days if possible.

D. Storage Summary

Form	Before Opening/Reconstitution	After Reconstitution/Opening
IV/IM powder vials (dry)	Store below 30°C. Protect from light and moisture. No refrigeration needed for dry powder.	SWFI: 5 hrs RT, 48 hrs fridge. NS: 24 hrs RT, 48 hrs fridge. D5W: 24 hrs RT, 24 hrs fridge. Discard remainder.
Oral tablets (cefuroxime axetil)	Store below 30°C. Protect from moisture. Keep in original blister/strip.	N/A — use within shelf life.
Oral suspension (dry powder before reconstitution)	Store below 30°C. Protect from moisture.	After reconstitution: 10 days at RT (≤25°C) or 10 days refrigerated. Discard after 10 days. In hot climate: refrigerate.

E. Cold-Chain Guidance

Cefuroxime dry powder (vials, tablets, dry syrup) does NOT require cold-chain storage. Stable at room temperature up to 30°C.
After reconstitution (IV solution or oral suspension): refrigeration extends stability — recommended in Indian climates.
No special transport cold-chain requirements for dry formulations.
ℹ️ Indian context: Cefuroxime’s room-temperature stability for dry formulations makes it suitable for supply to PHCs, CHCs, and remote areas without cold-chain infrastructure — unlike some reconstituted biologics or temperature-sensitive drugs.

RENAL ADJUSTMENT

⚠️ Cefuroxime is ~85–95% renally eliminated unchanged — dose adjustment IS required in significant renal impairment. This is similar to cefazolin and contrasts with nafcillin (hepatically cleared — no renal adjustment) and ceftriaxone (dual renal + biliary — usually no renal adjustment).

eGFR formula basis: Dosing adjustments below based on Creatinine Clearance (CrCl) by Cockcroft-Gault. CKD-EPI eGFR may be used as practical substitute but may overestimate renal function in elderly/low-muscle-mass Indian patients.

Adult Renal Dosing Adjustment Table — Parenteral (Cefuroxime Sodium)

CrCl (mL/min)	Dose Adjustment	Notes
>20	✅ No adjustment. Standard dosing: 750 mg–1.5 g IV q8h.	—
10–20	750 mg IV every 12 hours (q12h)	⚠️ Significant half-life prolongation. Extend interval from q8h to q12h. For severe infections: may use 1.5 g q12h.
<10 (non-dialysis)	750 mg IV every 24 hours (q24h)	⚠️ Marked accumulation. Extended interval essential. Monitor for adverse effects.
Haemodialysis	750 mg IV after each HD session (supplemental dose). Between HD days: 750 mg q24h.	⚠️ Cefuroxime IS significantly removed by HD (~50% removal during standard 4-hour session). Supplemental dose post-HD is MANDATORY. Timing: give at the END of HD session. On non-HD days: 750 mg q24h. For thrice-weekly HD: dose post-HD + additional dose between sessions if >48-hour inter-dialytic gap.
Peritoneal dialysis	750 mg IV every 12 hours (q12h)	Cefuroxime is NOT efficiently removed by continuous ambulatory PD. Dosing based on residual CrCl (typically <10 mL/min in PD patients).
CRRT (CVVH, CVVHD, CVVHDF)	750 mg–1.5 g IV every 12 hours (q12h)	CRRT provides continuous clearance (~equivalent to CrCl 20–40 mL/min depending on CRRT settings). Adjust based on effluent rate and infection severity. Consult ICU pharmacist/ID specialist.

Adult Renal Dosing — Oral (Cefuroxime Axetil)

CrCl (mL/min)	Dose Adjustment	Notes
>30	✅ No adjustment. Standard: 250–500 mg oral q12h WITH FOOD.	—
10–30	Standard dose — no formal dose reduction per most references. However, half-life is prolonged and some accumulation occurs.	ℹ️ Some experts recommend using 250 mg q12h (rather than 500 mg q12h) for non-severe infections in this CrCl range. Since oral bioavailability is only ~37–52%, total systemic exposure even at standard oral doses may be lower than with equivalent parenteral doses — providing a margin of safety.
<10	250 mg oral q24h (or consider IV/IM route for more predictable levels)	Marked half-life prolongation with oral route.
Haemodialysis	Give standard oral dose + supplemental 250 mg dose after each HD session	—

⚠️ Key practical note — Surgical Prophylaxis in CKD:
For patients with CKD undergoing elective surgery: give the standard pre-operative prophylactic dose (1.5 g IV) regardless of renal function — a single prophylactic dose does NOT require renal adjustment. The prolonged half-life in CKD actually extends tissue coverage post-operatively. Post-operative prophylactic doses (if given within 24 hours) should be adjusted per CrCl.

Paediatric Renal Adjustment

CrCl (mL/min/1.73 m²)	Dose Adjustment
>20	No adjustment. Standard weight-based dosing.
10–20	Standard per-dose amount; extend interval to q12h.
<10	Standard per-dose amount; extend interval to q24h.
Haemodialysis	Supplemental dose post-HD. Paediatric nephrologist involvement.

ℹ️ Paediatric renal function estimation: Use the Schwartz formula (bedside CKiD equation).

Augmented Renal Clearance (ARC)

⚠️ Clinically relevant for ICU patients on cefuroxime:

ARC (CrCl >130 mL/min) can significantly increase cefuroxime clearance → subtherapeutic levels with standard q8h dosing.
Common in: young adults with sepsis, polytrauma, burns, neurosurgical patients.
Action in ARC:
1. Increase frequency: 1.5 g IV q6h (instead of q8h) — or use maximum dose q6h.
2. Consider continuous infusion strategy (total daily dose in 24-hour NS infusion — specialist ICU protocol).
3. If available: TDM to confirm adequate free drug concentrations (rarely available for cefuroxime in India).

HEPATIC ADJUSTMENT

✅ NO HEPATIC DOSE ADJUSTMENT IS REQUIRED — EVER.

Rationale: Cefuroxime undergoes ZERO hepatic metabolism. It is excreted 100% unchanged by the kidneys. There are no active or inactive metabolites. Hepatic impairment — of any severity — has absolutely no effect on cefuroxime pharmacokinetics. This is identical to cefazolin.

Hepatic Impairment	Dose Adjustment
Child-Pugh A	✅ No adjustment.
Child-Pugh B	✅ No adjustment.
Child-Pugh C	✅ No adjustment.
Acute liver failure	✅ No adjustment.

ℹ️ Cefuroxime does NOT cause clinically significant hepatotoxicity — no hepatocellular injury, no cholestatic DILI. Transient mild LFT elevations (~1–2%) may occur (likely infection-related rather than drug-related). No routine LFT monitoring is needed for cefuroxime.

💡 Clinical advantage in liver disease: For patients with cirrhosis, hepatitis, ATT-induced DILI, or any liver disease requiring an antibiotic with respiratory + gram-negative coverage: cefuroxime (zero hepatic metabolism, zero hepatotoxicity) is a safe choice — similar to cefazolin. This contrasts with amoxicillin-clavulanate (clavulanate → cholestatic DILI risk), flucloxacillin (high DILI risk), and fluoroquinolones (hepatotoxicity reports).

Concurrent Hepatotoxin Note

✅ Cefuroxime poses NO additive hepatotoxicity risk when combined with hepatotoxic drugs:

Anti-TB drugs (rifampicin, isoniazid, pyrazinamide): no additive liver risk from cefuroxime
Methotrexate: no hepatic interaction from cefuroxime (though possible renal competition — see Drug Interactions)
Valproate: no hepatic interaction
Antiretrovirals: no hepatic interaction
Paracetamol: no hepatic interaction

CONTRAINDICATIONS

⛔ Absolute contraindications — the drug must NEVER be used:

1. ⛔ Known severe hypersensitivity (anaphylaxis) to cefuroxime or any cephalosporin

Rationale: Risk of recurrent IgE-mediated anaphylaxis — potentially fatal. Includes documented angioedema, severe urticaria with hypotension, laryngospasm, or bronchospasm to any cephalosporin.
ℹ️ Mild, delayed, non-IgE-mediated reactions to other cephalosporins (maculopapular rash without systemic features) are NOT absolute contraindications to cefuroxime but require cautious use with monitoring.

Allergy cross-reactivity:

Related Drug Class	Cross-Reactivity with Cefuroxime	Clinical Implication
Other cephalosporins (all generations)	Variable — depends on R1/R2 side chain similarity. Overall cross-reactivity between cephalosporins with different side chains: ~1–5%. Cefuroxime has a unique R1 side chain (methoxyimino group) — shared with some third-generation cephalosporins (cefotaxime, ceftriaxone have similar methoxyimino groups). Cross-reactivity between cefuroxime and these third-gen agents may be slightly higher (~2–5%) than with unrelated cephalosporins.	If anaphylaxis to cefuroxime: avoid ALL cephalosporins without formal allergy evaluation. If anaphylaxis to a cephalosporin with a very different side chain (e.g., cefazolin — tetrazole side chain, very different from cefuroxime): cefuroxime MAY be usable with specialist allergy consultation.
Penicillins (amoxicillin, ampicillin, cloxacillin, etc.)	~2–5% overall cross-reactivity.	For patients with non-severe penicillin allergy (rash, mild urticaria): cefuroxime CAN be used with monitored first dose. For patients with severe penicillin anaphylaxis: use with caution — formal allergy evaluation preferred. Many Indian and international guidelines accept cefuroxime in non-severe penicillin allergy.
Carbapenems	<1% cross-reactivity with cephalosporins	Safe in cephalosporin-allergic patients
Monobactams (aztreonam)	No cross-reactivity	✅ Safe in all beta-lactam-allergic patients

Penicillin Allergy Decision Table for Cefuroxime:

Allergy Severity	Description	Can Cefuroxime Be Given?	Action Required
🟢 MILD	Non-urticarial rash, >10 years ago, childhood, vague history	✅ YES	Monitored first dose (30 min observation). Low risk (~2%).
🟡 MODERATE	Urticaria, localised angioedema, within last 10 years	✅ YES — with caution	Monitored first dose in anaphylaxis-ready setting. Consider allergy consultation.
🔴 SEVERE	Anaphylaxis, severe angioedema, bronchospasm, hypotension	⚠️ CAUTION	Skin testing if available → if negative: cefuroxime safe. If skin testing unavailable: use non-beta-lactam alternative (azithromycin for respiratory infections; fluoroquinolone if appropriate).
⚪ UNCERTAIN	“Someone told me I’m allergic,” no documentation	✅ YES	Monitored first dose. Most common scenario — 80–90% are NOT truly allergic.

2. ⛔ Known anaphylaxis to cefuroxime specifically

⛔ Avoid cefuroxime. Other cephalosporins with different side chains may be usable after formal allergy evaluation.
Use alternative antibiotics: azithromycin (for respiratory infections), fluoroquinolone (levofloxacin/moxifloxacin for CAP), cotrimoxazole (for UTI), or vancomycin (for MSSA if all beta-lactams contraindicated).

CAUTIONS

⚠️ High-Priority Cautions

1. ⚠️ Renal Impairment — Dose Adjustment Required

Cefuroxime is ~85–95% renally eliminated. Dose interval extension is necessary when CrCl <20 mL/min (parenteral) or <30 mL/min (oral — conservative approach).
Monitoring: Serum creatinine at baseline and periodically. Calculate CrCl before prescribing — especially in elderly Indian patients where “normal” creatinine may mask CKD.
See Renal Adjustment table above.

2. ⚠️ Haemodialysis Patients — Supplemental Dosing Required

Cefuroxime is ~50% removed by standard HD. Post-HD supplemental dose MANDATORY.
Failure to supplement → subtherapeutic levels for the post-HD period → treatment failure.

3. ⚠️ Oral Cefuroxime Axetil — MUST Be Taken With Food

⚠️ This is clinically critical and is one of the most commonly overlooked prescribing instructions. Failure to take with food → ~40–50% reduction in bioavailability → subtherapeutic levels → treatment failure → unnecessary escalation to broader-spectrum agents.
Monitoring: If a patient on oral cefuroxime is not responding at 48–72 hours → FIRST ask: “Are you taking it with food?” before concluding treatment failure.

4. ⚠️ ESBL-Producing Organisms — NOT Covered

⚠️ In Indian hospital settings, ESBL prevalence is 40–70% among E. coli and Klebsiella. Cefuroxime is COMPLETELY INEFFECTIVE against ESBL producers.
Action: Always obtain cultures before empiric use for UTIs and gram-negative infections. If ESBL confirmed: switch immediately (nitrofurantoin for lower UTI, carbapenem or piperacillin-tazobactam for complicated UTI/systemic infections).

5. ⚠️ Penicillin Allergy — Cross-Reactivity Assessment

Cross-reactivity ~2–5%. For non-severe allergy: can use with monitored first dose. For severe anaphylaxis: formal allergy evaluation or alternative agent.
See cross-reactivity table under Contraindications.

6. ⚠️ Clostridioides difficile Infection (CDI) Risk

All cephalosporins carry CDI risk. Second-generation cephalosporins (cefuroxime) carry LOWER CDI risk than third-generation cephalosporins (ceftriaxone — one of the highest-risk antibiotics for CDI). This is a stewardship advantage of using cefuroxime instead of ceftriaxone when the narrower spectrum is adequate.
⚠️ Nevertheless, CDI can occur — especially in elderly, hospitalised, PPI-using, recently antibiotic-treated patients.
Monitoring: Report new-onset watery diarrhoea. Test for C. difficile toxin if suspected. Use shortest effective course.

7. ⚠️ Prolonged Surgical Prophylaxis (>24 Hours)

⛔ Same stewardship principle as cefazolin — do NOT continue prophylaxis >24 hours post-operatively. No evidence of benefit; increases AMR and CDI risk.

8. ⚠️ Intracameral Use — Dilution Error Risk

⚠️ For intracameral cefuroxime (endophthalmitis prophylaxis after cataract surgery): the dose is 1 mg in 0.1 mL — a 1000-fold dilution from the standard 750 mg vial. Dilution errors can cause toxic anterior segment syndrome (TASS) or retinal toxicity at higher doses, or prophylaxis failure at lower doses.
⚠️ Specialist ophthalmology use ONLY. Must follow the precise dilution protocol (see Part 2). Use a 1 mL tuberculin syringe. Prepare fresh for each patient. Pre-prepared commercially available intracameral formulations (if available) reduce dilution error risk.

Standard Cautions

9. Superinfection

Oral candidiasis, vaginal candidiasis, antibiotic-associated diarrhoea — standard antibiotic caution. Risk lower than with third-generation cephalosporins (narrower spectrum = less flora disruption).

10. Seizure History

Very high-dose cephalosporins in renal impairment can rarely lower seizure threshold. Risk with cefuroxime at standard doses is very low. Adjust dose per renal function.

11. Impact on Laboratory Tests

False-positive urine glucose: With copper-reduction methods (Benedict’s test, Clinitest). ✅ Enzymatic methods (glucose oxidase — glucometer strips) are NOT affected.
False-positive direct Coombs test (DAT): Possible — may complicate crossmatching. Clinical haemolysis is very rare.
Interference with ferricyanide-based glucose assays: Cefuroxime can cause false LOW blood glucose readings with some point-of-care glucose monitoring systems that use the dehydrogenase-pyrroloquinoline quinone (GDH-PQQ) method. ⚠️ In hospitalised patients receiving IV cefuroxime: verify that the ward glucometer uses a glucose oxidase-based or GDH-FAD/GDH-NAD-based test strip (NOT GDH-PQQ). This is particularly relevant in Indian ICUs where multiple glucometer brands are used.

12. Paediatric Palatability

⚠️ Cefuroxime axetil oral suspension has one of the worst tastes among commonly prescribed paediatric antibiotics — intensely bitter. This is a well-recognised clinical problem leading to:
- Refusal/spitting out the medicine → incomplete dosing → treatment failure
- Vomiting immediately after administration → lost dose
- Caregiver frustration → premature discontinuation
Action: If compliance is an issue: switch to a better-tasting alternative (amoxicillin-clavulanate, cefpodoxime proxetil, cefixime, or — for gram-positive-only infections — cephalexin). Document the taste issue as the reason for switching.

13. Neonatal Use

Extended dosing intervals (q8–12h) due to renal immaturity. NICU supervision required.
⛔ NOT for empiric neonatal sepsis (no Listeria or enterococcal coverage).

14. Sodium Content

Cefuroxime sodium contains approximately 2.4 mEq sodium per gram. At maximum dosing (6 g/day → ~14 mEq sodium/day from drug alone). In sodium-restricted patients (heart failure, cirrhosis): factor into total sodium budget. Generally clinically insignificant at standard doses.

15. Gonococcal Infections

⛔ Do NOT use cefuroxime for gonorrhoea — gonococcal resistance to cefuroxime is widespread in India and globally. Use ceftriaxone per NACO/ICMR guidelines. This is listed under Cautions (not Contraindications) because it is a treatment failure risk rather than a safety risk — but the clinical consequence (untreated gonorrhoea with complications) is serious.

16. Oral Tablets — Do NOT Crush

Film-coated tablets must be swallowed whole. Crushing releases intensely bitter taste → vomiting/refusal + potential bioavailability reduction. If patient cannot swallow tablets: use oral suspension formulation or switch to IV cefuroxime.

PREGNANCY

Overall Safety Statement

Cefuroxime is considered SAFE and COMPATIBLE with use in pregnancy. Cephalosporins as a class have extensive pregnancy safety data spanning decades, with no consistent teratogenic signal. Cefuroxime is one of the most widely used injectable antibiotics during pregnancy — particularly for caesarean section prophylaxis and treatment of UTIs and respiratory infections in pregnant women.

Former US-FDA Pregnancy Category: B (animal reproduction studies have not demonstrated fetal risk; extensive clinical experience supports safety).

Trimester-Specific Risk Assessment

Trimester	Risk Assessment	Details
First Trimester (Weeks 1–12)	Low risk — Compatible	No consistent evidence of teratogenicity with cephalosporin-class drugs. The organogenesis window (weeks 3–8 post-conception) does not appear to be affected. Large registry data (Swedish Medical Birth Registry, Hungarian Case-Control Surveillance of Congenital Abnormalities) for cephalosporin exposure in early pregnancy shows no increased malformation risk. First-trimester cephalosporin use for UTI treatment is well-established and considered safe.
Second Trimester (Weeks 13–26)	Low risk — Compatible	No specific concerns. Maternal PK changes (increased GFR, expanded plasma volume) accelerate cefuroxime clearance — serum levels may be 20–30% lower than non-pregnant women at the same dose. Standard doses remain adequate for most infections.
Third Trimester (Weeks 27–40)	Low risk — Compatible	Continued increased renal clearance. Cefuroxime crosses the placenta — fetal cord blood levels reach approximately 25–50% of maternal serum levels. This transplacental transfer is therapeutically advantageous for C-section prophylaxis (neonatal protection). No documented late-pregnancy or neonatal toxicity with cefuroxime.

Key Obstetric Uses

Obstetric Indication	Status	Notes
Caesarean section prophylaxis	✅ Standard alternative to cefazolin	Cefuroxime 1.5 g IV within 60 minutes before skin incision. ℹ️ Cefazolin is the globally preferred C-section prophylactic agent (FOGSI, ACOG, WHO guidelines). Cefuroxime is a valid alternative — slightly broader gram-negative coverage than cefazolin but otherwise equivalent. In Indian practice, both cefazolin and cefuroxime are commonly used for C-section prophylaxis.
UTI / Pyelonephritis in pregnancy	✅ Compatible	IV cefuroxime for hospitalised pyelonephritis (non-ESBL organism confirmed on culture). Oral cefuroxime axetil WITH FOOD for mild-moderate UTI. ⚠️ Always culture-guided — ESBL prevalence in Indian uropathogens limits empiric use. Alternative: oral cephalexin (NLEM, widely available, can be taken with food) for uncomplicated lower UTI.
CAP in pregnancy	✅ Compatible	For non-severe hospitalised CAP: IV cefuroxime ± macrolide. Oral step-down to cefuroxime axetil WITH FOOD. Safe and appropriate.
GBS intrapartum prophylaxis	ℹ️ NOT the standard first-line	First-line for GBS IAP: IV penicillin G or IV ampicillin. Cefazolin is the first-line alternative for penicillin-allergic patients (non-severe allergy). Cefuroxime is an acceptable but less commonly used alternative.

Preferred Alternatives in Indian Obstetric Practice

Situation	Alternative
C-section prophylaxis	Cefazolin 2 g IV — preferred first-line per FOGSI/ACOG
UTI (mild, outpatient) in pregnancy	Oral cephalexin 500 mg q6h (NLEM, pregnancy-safe) or nitrofurantoin (avoid near term)
Pyelonephritis in pregnancy (IV required)	Cefuroxime IV OR ceftriaxone IV (if ESBL not suspected)
MRSA infection in pregnancy	Vancomycin IV; clindamycin (if susceptible)

Monitoring During Pregnancy

Mother: Standard adverse effect monitoring. Renal function (pregnancy increases GFR — relevant for cefuroxime clearance but standard doses adequate). No LFT monitoring needed (zero hepatic metabolism/hepatotoxicity).
Fetus/Neonate: No specific fetal monitoring required for standard courses. No known fetal toxicity.

Pre-Conception Counselling

Not applicable — cefuroxime is an acute/short-course antibiotic. No pre-conception washout. No contraception requirement.

Pregnancy Prevention Programme / Registry

Not applicable.

Fertility Effects

No known adverse effect on male or female fertility. No washout period before planned conception required.

LACTATION

Overall Compatibility

✅ COMPATIBLE WITH BREASTFEEDING — Cefuroxime is considered safe during breastfeeding. Cephalosporins as a class have extensive lactation safety data.

Parameter	Details
Excretion into breast milk	Present in breast milk in low concentrations. The moderate protein binding (~33–50%) allows some transfer, but absolute amounts reaching the infant are clinically insignificant.
Relative Infant Dose (RID)	~0.2–1.0% of the maternal weight-adjusted dose (based on available PK data) — well below the 10% threshold considered generally safe.
Qualitative milk level	Very low.
Infant risk	Very low. Possible minor effects: transient alteration of bowel flora (mild loose stools), nappy rash. Oral candidiasis — uncommon. Allergic sensitisation — theoretical, not clinically demonstrated.
Compatibility statement	✅ Compatible with breastfeeding. No need to discontinue breastfeeding during cefuroxime therapy (IV or oral).

Monitoring in Breastfed Infant

Loose stools or mild diarrhoea (most common — transient)
Nappy rash
Oral thrush (uncommon)
Skin rash or allergic reaction (very rare)

Timing Advice

ℹ️ For IV cefuroxime: dosing schedule is fixed by nursing staff. Breastfeed at any time. For oral cefuroxime axetil: take WITH food (meal time); breastfeed at any time. Timing relative to doses is NOT critical given the very low RID.

Effect on Milk Production

No known effect on milk production.

Temporary Incompatibility

Not applicable — fully compatible with breastfeeding. No “pump and discard” period required.

ELDERLY

Definition: ≥60 years.

Dosing in Elderly

Parameter	Recommendation
Starting dose	⚠️ Dose per RENAL FUNCTION — not age. Calculate CrCl (Cockcroft-Gault) before prescribing. Many elderly Indian patients with “normal” serum creatinine (1.0–1.2 mg/dL) have CrCl of only 30–50 mL/min due to low muscle mass — requiring interval adjustment for parenteral cefuroxime. Standard oral dosing (250–500 mg q12h) is usually adequate if CrCl >30 mL/min.
Titration	Not applicable.

Extra Risks Specific to Elderly

Risk	Details	Monitoring / Action
⚠️ Occult renal impairment	THE most important elderly concern for cefuroxime (same as cefazolin). Cefuroxime is ~85–95% renally eliminated — accumulation occurs if renal function is not assessed.	MANDATORY: Calculate CrCl before prescribing. Do NOT rely on serum creatinine alone. If CrCl <20 mL/min: parenteral q12h instead of q8h.
CDI risk	Elderly are the highest-risk group for CDI. Cefuroxime carries lower CDI risk than ceftriaxone (stewardship advantage) — but CDI can still occur.	Monitor for diarrhoea. Use shortest effective course. Review PPI indication.
Oral cefuroxime — food adherence	Elderly patients with poor appetite, anorexia of illness, or irregular eating may struggle with the “take with food” requirement.	If food intake is unreliable: consider IV/IM cefuroxime (ensures full bioavailability) or switch to an oral antibiotic without a food requirement (e.g., amoxicillin-clavulanate — also should be taken with food but less bioavailability-dependent; cephalexin — minimal food effect).
Polypharmacy	💡 Cefuroxime’s clean drug interaction profile (no CYP interactions, no hepatic metabolism) is a significant advantage in elderly patients on multiple medications. No warfarin CYP interaction (unlike dicloxacillin/nafcillin). No calcineurin inhibitor interaction.	Minimal additional drug interaction monitoring needed beyond standard antibiotic cautions.
Phlebitis	Elderly have fragile veins — moderate phlebitis risk with cefuroxime (~5–10%).	Adequate dilution, slow infusion, rotate IV sites. Consider PICC for courses >5 days.
Falls / Delirium	Cefuroxime does NOT cause sedation, dizziness, or confusion. No falls risk contribution. Advantage over fluoroquinolones (which are associated with delirium, confusion, tendon rupture in elderly).	No specific falls precaution.

Common Clinical Scenarios in Elderly Indian Patients

Scenario	Guidance
Elderly patient with CAP — outpatient (CURB-65 = 1)	Oral cefuroxime axetil 500 mg q12h WITH FOOD (confirm food intake is adequate) ± oral azithromycin 500 mg OD for atypical coverage. If food intake is poor: use amoxicillin-clavulanate instead or hospitalise for IV therapy. Check CrCl — adjust if <30 mL/min.
Elderly patient with AECOPD and purulent sputum	Oral cefuroxime axetil 500 mg q12h WITH FOOD × 5 days. Check CrCl. Appropriate for moderate AECOPD with bacterial suspicion.
Elderly patient with pyelonephritis — CrCl 25 mL/min	IV cefuroxime 750 mg q12h (adjusted for CrCl 10–20 range). ⚠️ Obtain urine C&S — ESBL prevalence in elderly Indian uropathogens is high. If ESBL confirmed: switch to carbapenem or piperacillin-tazobactam.
Elderly patient undergoing elective hernia repair	Cefuroxime 1.5 g IV (or cefazolin 2 g IV — either acceptable) within 60 minutes before incision. Single dose. No post-operative prophylaxis extension (clean surgery).

Anticholinergic Burden

No anticholinergic burden. Cefuroxime has no anticholinergic properties. ACB score = 0.

Beers Criteria / STOPP-START Relevance

Cefuroxime is NOT listed in Beers Criteria or STOPP criteria. No age-based restriction.

Deprescribing Guidance

Deprescribing: Not applicable — acute/short-course antibiotic. Ensure course completion and appropriate IV-to-oral step-down.

MAJOR DRUG INTERACTIONS

💡 Cefuroxime has an EXCEPTIONALLY CLEAN drug interaction profile — no CYP450 substrate/inhibitor/inducer activity, no hepatic metabolism, no significant drug transporter interactions. This is one of the drug’s major practical advantages, especially for elderly patients on polypharmacy and for patients on warfarin, calcineurin inhibitors, or antiretrovirals.

The interactions below are primarily pharmacodynamic (class-effect of antibiotics) or physical/chemical (IV incompatibilities).

Interacting Drug / Substance	Mechanism	Clinical Effect	Onset Type	Action Required
⚠️ Aminoglycosides (Gentamicin, Amikacin, Tobramycin)	Physical/chemical incompatibility when mixed in same IV solution/line — beta-lactam ring reacts with aminoglycoside amino groups → inactivation of BOTH drugs. Pharmacodynamic synergy: When given via separate lines, beta-lactam + aminoglycoside provides synergistic bactericidal killing (exploited therapeutically in some severe infections).	(1) Incompatibility: Loss of both drugs’ activity if co-mixed. (2) Synergy: Enhanced killing when administered correctly via separate lines (therapeutic benefit). In patients with severe renal impairment: in-vivo inactivation of aminoglycosides by accumulated beta-lactam may also occur.	Incompatibility: immediate on contact. Synergy: immediate from first dose.	⛔ NEVER mix in same IV bag, syringe, or line. Administer through separate IV lines or flush with ≥20 mL NS between drugs (≥30-minute separation). Monitor aminoglycoside levels in renal impairment.
⚠️ Warfarin / Acenocoumarol	Pharmacodynamic (NOT CYP-mediated): Gut flora disruption → reduced bacterial vitamin K synthesis → modest potentiation of anticoagulant effect → INR increase. ℹ️ Cefuroxime does NOT induce CYP3A4 (unlike nafcillin/dicloxacillin) → NO enzyme-mediated warfarin interaction. INR change is modest, predictable, and unidirectional (increase only). No post-discontinuation INR rebound.	⚠️ Modest, predictable INR increase. Lower interaction severity than warfarin + nafcillin/dicloxacillin.	Gradual onset — 3–7 days.	Check INR at day 3–5. Repeat weekly during concurrent use. Adjust warfarin/acenocoumarol. ℹ️ India-specific: Acenocoumarol (Acitrom) is more common than warfarin in India — same monitoring applies.
⚠️ Probenecid	Probenecid inhibits renal tubular secretion of cefuroxime (OAT1/OAT3 competition) → reduced renal clearance → increased cefuroxime AUC (~50% increase) and prolonged half-life.	Increased and prolonged cefuroxime levels. At standard doses, accumulation is within the wide therapeutic index. Historically exploited to boost levels — rarely done today.	Immediate — from first concurrent dose.	ℹ️ No dose adjustment usually needed. Monitor for adverse effects if prolonged concurrent use. Probenecid is infrequently used in current Indian practice.
⚠️ Live oral vaccines (Ty21a oral typhoid, oral cholera vaccine)	Antibacterial activity can theoretically inactivate live bacterial vaccine strains.	⚠️ Reduced vaccine efficacy.	Immediate.	Wait ≥3 days (preferably 7 days) after completing cefuroxime before administering oral live bacterial vaccines. Injectable vaccines NOT affected.
⚠️ Antacids / H2 blockers (Oral cefuroxime axetil only)	Antacids (aluminium/magnesium hydroxide) and H2 receptor blockers (ranitidine, famotidine) reduce gastric acidity → may modestly reduce cefuroxime axetil absorption. The ester bond hydrolysis is not significantly pH-dependent, but some studies show ~20–30% reduction in Cmax (not AUC) with antacids.	Modest reduction in peak oral cefuroxime levels. Clinical significance is debated — likely insignificant at standard doses WITH FOOD (food is the dominant absorption enhancer).	Immediate.	ℹ️ If possible: take cefuroxime axetil ≥1 hour before or 2 hours after antacids. In practice, the food effect (↑40–50% bioavailability) is far more important than the antacid effect (↓20–30%). Prioritise the food instruction — if the patient takes cefuroxime with food but also takes an antacid at the same meal, the net bioavailability is still adequate. PPIs: no significant interaction with cefuroxime absorption (PPIs do NOT reduce cefuroxime axetil absorption meaningfully).

Major Food-Drug and Herb-Drug Interactions

Substance	Mechanism	Clinical Effect	Action
⚠️ FOOD (oral cefuroxime axetil)	Food increases oral bioavailability by ~40–50% by slowing gastric emptying → prolonging intestinal esterase contact time → more complete hydrolysis of the prodrug → more active cefuroxime absorbed.	Food INCREASES efficacy — this is a POSITIVE interaction that must be EXPLOITED, not avoided. Taking on empty stomach → subtherapeutic levels → treatment failure risk.	⚠️ ALWAYS take oral cefuroxime WITH FOOD. This is the single most important administration instruction. Write on every prescription. Counsel every patient.
Traditional medicine: Giloy / Guduchi (Tinospora cordifolia)	No pharmacokinetic interaction with cefuroxime (zero hepatic metabolism, no CYP involvement). Giloy-associated hepatotoxicity (DILI reports) is a separate concern. ℹ️ Cefuroxime has ZERO hepatotoxicity — no additive hepatic concern when combined with Giloy (unlike amoxicillin-clavulanate where clavulanate DILI risk adds to Giloy risk).	No clinically significant interaction.	ℹ️ No specific concern from a cefuroxime perspective. General advice: disclose herbal supplements to doctors.

MODERATE DRUG INTERACTIONS

Interacting Drug / Substance	Mechanism	Clinical Effect	Onset Type	Action Required
Metformin	No direct pharmacokinetic interaction. Acute infection + hospitalisation independently destabilise glycaemic control.	Altered glycaemic control (indirect — infection, not drug-drug interaction).	Immediate (infection effect).	Monitor blood glucose in diabetic patients. Hydration. Hold metformin if severe sepsis/renal deterioration/contrast exposure.
Oral Contraceptive Pills (COCPs)	ℹ️ No CYP-mediated interaction. Theoretical gut flora disruption → reduced enterohepatic recirculation of ethinylestradiol. Clinical evidence does NOT support reduced COCP efficacy with non-enzyme-inducing antibiotics (including cefuroxime).	ℹ️ No clinically significant interaction.	N/A	ℹ️ No additional contraceptive precautions needed. Exception: if severe diarrhoea/vomiting impairs COCP absorption → advise barrier contraception until 7 days after GI symptoms resolve.
Cyclosporine / Tacrolimus	ℹ️ No CYP3A4 interaction (cefuroxime does not affect CYP). No significant effect on calcineurin inhibitor levels.	ℹ️ No clinically significant interaction. Safe for transplant patients.	N/A	ℹ️ Cefuroxime is safe with calcineurin inhibitors — no dose adjustment of immunosuppressant needed. Advantage over nafcillin/dicloxacillin (CYP3A4 inducers).
Voriconazole	ℹ️ No CYP interaction.	ℹ️ No interaction.	N/A	✅ Safe with voriconazole.
Methotrexate	Possible reduced renal tubular secretion (penicillin/cephalosporin class effect — OAT competition). However, clinical significance with cefuroxime specifically is uncertain and rarely reported.	Theoretical increased methotrexate toxicity — primarily with high-dose methotrexate (oncologic doses). Low risk with low-dose methotrexate (RA/psoriasis).	Acute onset (renal competition).	ℹ️ For high-dose methotrexate: avoid concurrent use if possible. If essential: monitor methotrexate levels, CBC, renal function. For low-dose methotrexate: monitor CBC.
GDH-PQQ glucometer test strips	⚠️ Cefuroxime can cause falsely LOW blood glucose readings with glucose monitoring systems using GDH-PQQ (glucose dehydrogenase-pyrroloquinoline quinone) test strips.	⚠️ Falsely low glucose readings — may mask hypoglycaemia or lead to under-treatment of hyperglycaemia in diabetic patients.	Immediate — during IV cefuroxime administration.	⚠️ In hospitalised patients receiving IV cefuroxime: verify that ward glucometers use glucose oxidase-based or GDH-FAD/GDH-NAD-based test strips (NOT GDH-PQQ). If GDH-PQQ strips are in use: switch to alternative monitoring system for the duration of cefuroxime therapy. Alert diabetology team and nursing staff.
Traditional medicine: Triphala	Mild laxative properties. Combined with antibiotic-associated GI effects: may worsen diarrhoea.	Additive GI disturbance.	Immediate.	Counsel to temporarily stop Triphala during antibiotic course if diarrhoea develops.

COMMON ADVERSE EFFECTS

ℹ️ Cefuroxime has a good overall tolerability profile — adverse effects are generally mild and similar to other cephalosporins. The most clinically relevant distinction is the bitter taste of oral suspension (a major paediatric compliance issue) and the moderate phlebitis rate with IV administration.

Very Common (≥10%)

ℹ️ None — no adverse effect occurs at ≥10% incidence with cefuroxime in clinical trials. This is a clean tolerability profile.

⚠️ ONE important caveat: While no single ADR reaches ≥10%, the combined GI symptom complex (nausea + diarrhoea + abdominal discomfort) with oral cefuroxime axetil may affect >10% of patients when all GI symptoms are pooled. Individual GI symptoms are typically <10% each.

Common (1–10%)

Adverse Effect	System	Details
Diarrhoea	GI	~3–8%. Disruption of gut flora. Usually mild, non-bloody, self-limiting. ✅ Lower incidence than amoxicillin-clavulanate (~10–25% with clavulanate). If severe/bloody/febrile → rule out CDI. More common with oral cefuroxime axetil than IV (oral route disrupts intestinal flora more directly).
Nausea	GI	~3–7%. More common with oral cefuroxime axetil (bitter taste contributes even when swallowed whole — some aftertaste). Taking WITH FOOD reduces nausea.
Vomiting	GI	~2–5%. More common in children (bitter suspension taste triggers vomiting). If vomiting within 30 minutes of oral dose: repeat the dose.
Abdominal pain / Discomfort	GI	~1–3%.
Phlebitis at IV site	Local	~5–10%. Moderate risk — higher than cefazolin (~1–5%) but lower than nafcillin/oxacillin (~10–30%). Mitigate: adequate dilution, infuse over ≥15 minutes, rotate IV sites q48–72h.
Pain at IM injection site	Local	~5–15% (of IM doses). Moderately painful — more so than many other IM cephalosporins. Reconstitute with 0.5% lidocaine to reduce pain.
Rash (maculopapular, non-urticarial)	Dermatological	~1–3%. Delayed, non-IgE-mediated reaction. Usually self-limiting.
Headache	CNS	~1–3%. Mild.
Transient eosinophilia	Haematological	~1–5%. Mild drug hypersensitivity phenomenon. If eosinophilia + rising creatinine → suspect AIN (very rare). If isolated eosinophilia with stable renal function: monitor, no action.
Transient LFT elevation	Hepatic	~1–2%. Very mild. NOT true hepatotoxicity (zero hepatic metabolism) — likely infection-related or coincidental. No clinical significance.
Oral candidiasis (thrush)	Oral	~1–2%. More common in elderly, immunocompromised, steroid users.
Vaginal candidiasis	Gynaecological	~1–3% in women.

Paediatric-Specific Common ADR

Adverse Effect

Details

⚠️ Bitter taste / Taste aversion (oral suspension)

⚠️ THE most clinically impactful common adverse effect of cefuroxime in paediatric practice. Cefuroxime axetil suspension has one of the worst tastes among commonly prescribed paediatric oral antibiotics — intensely bitter, difficult to mask even with flavouring. This leads to: refusal, spitting, vomiting immediately after dosing, and caregiver frustration → premature discontinuation → treatment failure. Incidence: Taste-related complaints in up to 30–40% of paediatric patients in clinical practice (though not formally reported as an ADR frequency in clinical trials). ℹ️ This single ADR is the primary reason many Indian paediatricians avoid oral cefuroxime in favour of better-tasting alternatives (amoxicillin-clavulanate, cefpodoxime proxetil, cefixime).

SERIOUS ADVERSE EFFECTS

⚠️ Report ALL serious adverse effects to the nearest ADR Monitoring Centre under PvPI (Pharmacovigilance Programme of India) or via the ADR reporting form on CDSCO website (www.cdsco.gov.in). PvPI Helpline: 1800-180-3024 (toll-free).

Adverse Effect	Frequency	Details	Action
⚠️ Anaphylaxis / Anaphylactic shock	Rare (~1–5 per 100,000 courses)	IgE-mediated Type I hypersensitivity. Onset: within 5–30 minutes of IV/IM dose; may be slightly delayed with oral route. Features: urticaria, angioedema, bronchospasm, laryngeal oedema, hypotension, cardiovascular collapse. Fatal if untreated.	⛔ STOP immediately. Administer Adrenaline (Epinephrine) 0.5 mg IM (0.5 mL of 1:1000) into anterolateral thigh. Repeat q5 min. Adjuncts: oxygen, IV NS bolus, salbutamol nebulisation, IV hydrocortisone 200 mg, IV chlorpheniramine 10 mg. ⛔ Lifetime ban on cefuroxime — formal allergy assessment before any future cephalosporin/penicillin. Adrenaline available at ALL levels of Indian healthcare. ⚠️ Report to PvPI.
⚠️ Clostridioides difficile-associated diarrhoea (CDAD)	Uncommon (~0.5–2% of hospitalised patients)	During therapy or up to 8 weeks after. Features: profuse watery/bloody diarrhoea, cramps, fever. Severe: toxic megacolon, perforation. ℹ️ Lower CDI risk than ceftriaxone (a stewardship advantage of second-generation over third-generation cephalosporins).	STOP cefuroxime. Test C. difficile toxin. Treat: oral vancomycin 125 mg QDS × 10 days (first-line). Fidaxomicin 200 mg BD × 10 days (lower recurrence). Metronidazole 500 mg TDS × 10 days if vancomycin unavailable. ⛔ No antimotility agents. ⚠️ Report to PvPI.
⚠️ Stevens-Johnson Syndrome (SJS) / Toxic Epidermal Necrolysis (TEN)	Very rare (<1 per 100,000)	Severe mucocutaneous reaction. Onset: 7–21 days. Prodromal fever → painful macules → blistering → epidermal detachment. Mucosal involvement. Mortality: SJS ~5%, TEN ~25–30%.	⛔ STOP immediately. Urgent dermatology + burns/ICU referral. Supportive care. Ophthalmology consult. ⛔ Avoid ALL cephalosporins lifelong without allergy evaluation. ⚠️ Report to PvPI.
⚠️ DRESS Syndrome	Very rare	Onset: 2–8 weeks. Fever + rash + eosinophilia + organ involvement (hepatitis, nephritis). Mortality ~5–10%.	⛔ STOP drug. Systemic corticosteroids. Monitor organ functions. ⛔ Avoid ALL cephalosporins lifelong. ⚠️ Report to PvPI.
Serum sickness-like reaction	Uncommon	Onset: 7–21 days. Fever, arthralgia, urticarial rash, lymphadenopathy. More common in children.	STOP drug. Antihistamines, NSAIDs, corticosteroids if severe. Self-limiting 1–3 weeks. ⚠️ Report to PvPI.
Interstitial Nephritis (AIN)	Very rare with cefuroxime	Immunoallergic reaction. Onset: 1–4 weeks. Rising creatinine, eosinophilia, sterile pyuria.	STOP drug. Supportive. Nephrology referral. Consider corticosteroids. Most recover. ⚠️ Report to PvPI.
Neutropenia (reversible)	Very rare at standard courses	Dose-dependent, reversible. After ≥2 weeks of high-dose therapy.	Monitor CBC for courses >14 days. If ANC <1000/µL: stop or reduce dose. Recovery within 5–10 days. ⚠️ Report to PvPI.
Haemolytic anaemia (Coombs-positive)	Very rare	IgG-mediated. Positive DAT. Usually mild.	Stop drug if clinically significant haemolysis. Haematology referral. ⚠️ Report to PvPI.
⚠️ Toxic Anterior Segment Syndrome (TASS) — Intracameral use only	Rare (related to DILUTION ERRORS)	⚠️ Occurs ONLY with intracameral cefuroxime — if dose >1 mg is inadvertently injected into the anterior chamber due to dilution error. Features: severe anterior chamber inflammation, corneal oedema, hypopyon, possible permanent visual impairment. NOT a pharmacological adverse effect at the correct dose — it is a dose error toxicity.	⚠️ Prevention is paramount: follow the precise dilution protocol (Part 2). Use pre-prepared commercially available formulations when available. If TASS suspected post-cataract surgery: urgent ophthalmology assessment, topical steroids, anterior chamber wash if severe. ⚠️ Report to PvPI.
Seizures / Neurotoxicity	Exceedingly rare	Only in massive overdose or severe renal impairment with accumulation. Risk much lower than with cefepime (well-documented neurotoxicity in renal failure) or imipenem.	Reduce dose per renal function. Benzodiazepine for seizure. ⚠️ Report to PvPI.

Antidote / Reversal Information

Toxicity	Antidote	Dose	India Availability
Anaphylaxis	Adrenaline (Epinephrine)	0.5 mg IM (1:1000) — repeat q5 min	✅ ALL levels
CDI	Oral Vancomycin	125 mg QDS × 10 days	✅ Available
Drug overdose / accumulation	Haemodialysis — cefuroxime IS removed by HD (~50%)	Standard 4-hour HD	✅ Available at district/tertiary hospitals
Seizures	Benzodiazepines	Lorazepam 2–4 mg IV or Diazepam 5–10 mg IV	✅ Available
TASS (intracameral overdose)	No antidote — anterior chamber wash, topical steroids, supportive ophthalmic care	—	Ophthalmology unit

Early Warning Signs — Patient/Caregiver/Nursing Staff Education

"⚠️ Report immediately if:

Skin rash with blisters, peeling, or sores in mouth/eyes/genitals
Swelling of face, lips, tongue, throat; difficulty breathing
Severe watery or bloody diarrhoea with cramps and fever
Reduced urine output or blood in urine
Unusual bruising or bleeding
For patients after eye surgery receiving this medicine in the eye: severe eye pain, redness, or sudden worsening of vision"

MONITORING REQUIREMENTS

Baseline (Before Starting)

Parameter	Priority	Details	Resource-Limited Setting Surrogate
Allergy history — beta-lactam	MANDATORY	Detailed history of previous penicillin or cephalosporin reactions. Classify as mild/moderate/severe using the Penicillin Allergy Decision Table (see Contraindications). Specifically ask about: prior cephalosporin use, prior penicillin use, nature of reaction (urticaria vs maculopapular rash vs anaphylaxis), timing (immediate <1 hr vs delayed), and whether rechallenge was ever done. This is the single most important pre-prescribing assessment for any beta-lactam.	Same — clinical history. No substitute.
Serum creatinine + eGFR/CrCl calculation	MANDATORY (for all parenteral therapy; for oral therapy in patients ≥60 years, known CKD, diabetes, concurrent nephrotoxic drugs) / RECOMMENDED (for short-course oral therapy in young adults with no risk factors)	Cefuroxime is ~85–95% renally eliminated. Dose interval adjustment required when CrCl <20 mL/min (parenteral) or <30 mL/min (oral — conservative approach). Use Cockcroft-Gault or CKD-EPI. ⚠️ In elderly Indian patients: always calculate — “normal” serum creatinine (0.9–1.2 mg/dL) frequently masks CrCl of 30–50 mL/min due to low muscle mass, vegetarian diet, and sarcopaenia.	If serum creatinine unavailable: assess urine output (>0.5 mL/kg/hr suggests adequate renal function), history of known kidney disease, oedema, and concurrent nephrotoxic drugs. Extend dosing interval conservatively (q12h parenteral) if renal function uncertain and patient is elderly or critically ill.
Infection-specific cultures	MANDATORY (for serious infections: sepsis, pyelonephritis, pneumonia requiring hospitalisation, bone and joint infections, endocarditis) / RECOMMENDED (for UTI — urine C&S before starting, especially in India due to high ESBL prevalence) / OPTIONAL (for uncomplicated sinusitis, AOM, mild SSTI)	Blood cultures (×2 sets from separate sites), urine C&S, sputum Gram stain/culture, wound swab C&S — as appropriate. Ideally obtained BEFORE first antibiotic dose. ⚠️ India-specific: For UTIs, urine C&S before starting cefuroxime is particularly important given ESBL prevalence of 20–40% even in community-acquired uropathogens in urban India.	If culture facilities unavailable (PHC/CHC): start empirical therapy, document clinical diagnosis carefully. Refer for culture if no response at 48–72 hours. For UTI: at minimum send urine for microscopy (pus cells, bacteria).
Complete blood count (CBC) with differential	RECOMMENDED	Baseline WBC, differential, haemoglobin, platelet count. Assesses infection severity and provides baseline for monitoring haematological ADRs (neutropenia, eosinophilia) if prolonged course anticipated.	If CBC unavailable: clinical assessment of pallor, petechiae, signs of severe infection.
CRP / Procalcitonin	RECOMMENDED (for hospitalised patients) / OPTIONAL (for outpatient oral therapy)	CRP is most useful for tracking therapeutic response — expect ≥50% decline by day 3–4. Procalcitonin (if available) helps distinguish bacterial vs viral infection and guide antibiotic discontinuation.	Fever curve and clinical assessment as primary surrogates.
Liver function tests (LFTs)	OPTIONAL	Cefuroxime has ZERO hepatic metabolism and ZERO clinically significant hepatotoxicity. Baseline LFTs are not routinely needed. May be obtained for completeness in hospitalised patients (to establish baseline in case of coincidental LFT changes during illness).	Not required.
Blood glucose monitoring system verification	RECOMMENDED (for hospitalised diabetic patients on IV cefuroxime)	⚠️ Verify that the ward glucometer uses glucose oxidase-based or GDH-FAD/GDH-NAD test strips — NOT GDH-PQQ strips. Cefuroxime can cause falsely LOW glucose readings with GDH-PQQ systems → may mask hypoglycaemia or lead to under-treatment of hyperglycaemia. Alert diabetology team and nursing staff.	If glucometer type cannot be verified: use venous blood glucose (laboratory assay) for monitoring during IV cefuroxime therapy.

For specific indications — additional mandatory baseline:

Indication	Additional Mandatory Baseline
Surgical prophylaxis	No additional monitoring beyond standard pre-operative assessment. Confirm drug allergy history. Confirm timing (within 60 min of incision).
UTI / Pyelonephritis	Urine C&S (MANDATORY). Renal ultrasound for complicated UTI, febrile UTI in children, or recurrent UTI.
Hospitalised CAP	Chest X-ray, SpO₂/ABG. Blood cultures ×2 (before antibiotics). Sputum Gram stain/culture if obtainable.
Intracameral use (ophthalmology)	Pre-operative ocular assessment (slit lamp, IOP). Confirm dilution protocol. No systemic monitoring needed for intracameral single dose.

After Initiation / Dose Change

Parameter	Timing	Details
Clinical response assessment	48–72 hours after starting therapy	Fever curve (defervescence expected by 48–72 hrs for most community-acquired infections), symptom improvement (respiratory, urinary, wound, etc.). ⚠️ If no improvement at 72 hours → systematic reassessment: (1) Is the patient taking oral cefuroxime WITH FOOD? (commonest correctable cause of apparent failure); (2) Review culture results — ESBL? MRSA? Resistant organism? (3) Alternative diagnosis? (TB, fungal, non-infectious); (4) Complication? (abscess, empyema, obstruction).
CRP	Day 3–5 (for hospitalised patients)	Declining CRP supports adequate treatment response. Persistently elevated or rising CRP → reassess.
Serum creatinine	Day 3–5 (for patients on IV therapy, or concurrent nephrotoxic drugs)	Recheck to detect early renal deterioration. Adjust cefuroxime interval if CrCl declines. Particularly important if combined with aminoglycosides or NSAIDs.
Repeat cultures	48–72 hours (for bloodstream infections only)	Repeat blood cultures to document clearance. Not routinely needed for UTI, CAP, or SSTI if clinical response is adequate.

Long-Term / Maintenance Monitoring

Parameter	Frequency	Details
CBC with differential	Weekly if therapy exceeds 14 days	Prolonged cefuroxime (rare in practice) can cause reversible neutropenia, thrombocytopenia, or eosinophilia. Most cefuroxime courses are 5–14 days — weekly CBC is relevant only for bone/joint infections or endocarditis where extended courses are used.
Serum creatinine / eGFR	Weekly during prolonged IV courses (>14 days)	Monitor for acute interstitial nephritis (very rare with cefuroxime). Also relevant if concurrent nephrotoxic agents.
LFTs	NOT routinely needed	Cefuroxime has zero hepatic metabolism and negligible hepatotoxicity risk. Mild transient LFT elevations (~1–2%) are usually infection-related, not drug-related. Check only if clinical suspicion of hepatic ADR (jaundice, dark urine — extremely rare).
Stool monitoring	Ongoing — clinical assessment	If diarrhoea develops (≥3 loose stools/day), especially if bloody, watery, or with fever → test for C. difficile toxin (GDH + toxin A/B or NAAT). CDI can occur during therapy or up to 8 weeks after stopping.
IV site assessment	Every shift (q8–12 hours) — nursing responsibility	Check for phlebitis (redness, swelling, pain along the vein), infiltration, extravasation. Cefuroxime has moderate phlebitis risk (~5–10% — higher than cefazolin). Rotate peripheral IV sites every 48–72 hours. For courses >5–7 days: consider midline or PICC insertion.

Therapeutic Drug Monitoring (TDM)

ℹ️ Routine TDM for cefuroxime is NOT performed. Cefuroxime has a wide therapeutic index. Dosing is standardised by weight (paediatric) and renal function (adult), and adjusted clinically rather than by serum level monitoring.

TDM may theoretically be considered (when available — rarely available for cefuroxime in India):

ICU patients with augmented renal clearance (ARC) — to confirm adequate levels with q6h dosing
Patients with severe renal impairment on dialysis — to confirm neither accumulation nor underdosing
Morbid obesity — if clinical response is poor despite standard dosing

Target levels (if TDM used):

No universally established therapeutic range. Key PK/PD target: free drug concentration above MIC for ≥40–50% of the dosing interval (%fT > MIC). For most susceptible organisms (MIC ≤ 4 mg/mL), standard dosing achieves this target.

When to stop monitoring: Monitoring (CBC, creatinine) can be stopped when:

The antibiotic course is completed
For courses ≤7 days in patients with normal renal function: no repeat monitoring necessary unless clinical concern

Resource-Limited Setting Surrogates — Summary Table

Monitoring Parameter	Clinical Surrogate When Test Unavailable
Serum creatinine / eGFR	Urine output monitoring (>0.5 mL/kg/hr). Oliguria/anuria history. Oedema. Known CKD history. Use conservative dosing intervals (q12h parenteral) if uncertain.
CBC	Clinical signs of anaemia (pallor, tachycardia), bleeding (petechiae, gum bleeding), worsening infection despite treatment (possible neutropenia).
CRP / Procalcitonin	Fever curve as primary surrogate. Subjective improvement (appetite, activity, pain).
Urine C&S	Urine microscopy (pus cells, bacteria — if microscope available). Clinical response assessment at 48–72 hours. If no response → refer for formal C&S.
Blood culture	Gram stain of buffy coat (if trained microbiologist available). Clinical response to empirical therapy. Refer if no improvement.
Glucometer verification	Use venous blood glucose (laboratory assay) if glucometer type cannot be confirmed for cefuroxime-treated diabetic patients.

PATIENT COUNSELLING

(Written in simple language for the prescribing doctor to convey to the patient during consultation)

What this medicine is for:
“This medicine is an antibiotic — it kills the bacteria (germs) causing your infection. It works against many types of germs that cause chest infections, ear infections, sinus infections, urine infections, and skin infections. It will NOT work against viruses (such as the common cold or flu).”

How to take it:

For tablets (oral cefuroxime axetil):

⚠️ “ALWAYS take this medicine WITH FOOD — with breakfast and dinner (or with a meal/snack). This medicine works MUCH BETTER when taken with food. If you take it on an empty stomach, your body will absorb only half the medicine — and the infection may not clear.”
“Take the tablet twice a day — once in the morning with breakfast and once in the evening with dinner.”
“Swallow the tablet whole with a glass of water. Do NOT crush, break, or chew the tablet — it has a very bitter taste inside.”
“Take your doses at regular times — about 12 hours apart (for example: 8 AM with breakfast and 8 PM with dinner).”
“Complete the full course as prescribed by your doctor, even if you feel better before the course is finished. Stopping early can allow the infection to come back, and the germs may become resistant.”

For liquid medicine (oral suspension — for children):

“Shake the bottle well before each dose.”
“Use the measuring cup or oral syringe given with the bottle — do NOT use a household spoon (it gives the wrong amount).”
⚠️ “Give with food or immediately after a meal.”
ℹ️ “This liquid has a bitter taste. Your child may not like it. You can try: (a) giving a small piece of chocolate or a sip of juice immediately after the medicine; (b) mixing the measured dose with a very small amount of chocolate syrup or honey (only for children over 1 year old) immediately before giving — but make sure the child takes ALL of the mixture. Do NOT mix into a full bottle of milk — if the child does not finish the bottle, the dose will be incomplete.”
“If your child vomits within 30 minutes of taking the medicine, give the same dose again. If vomiting happens after 30 minutes, do NOT repeat — the medicine has already been absorbed.”
“If your child keeps refusing or vomiting the medicine because of the taste, call your doctor — they may switch to a different medicine that tastes better.”

What to do if you miss a dose:

“If you remember within 6 hours of the missed time, take the dose immediately with food. Then continue your regular schedule.”
“If more than 6 hours have passed (that is, your next dose is due in less than 6 hours), skip the missed dose and take the next one at its normal time with food.”
“Never take two doses at the same time to make up for a missed dose.”

Common side effects to expect:

“You may get loose stools or mild diarrhoea — this is common and usually mild. Drink plenty of fluids (water, ORS, coconut water, buttermilk/chaas). If the diarrhoea is very severe, watery, bloody, or lasts more than 2 days, see your doctor.”
“You may feel mild nausea or stomach discomfort — taking the medicine with food (as instructed) helps reduce this.”
“The injection form may cause pain at the drip site (vein) — tell the nurse if you notice redness, swelling, or pain at the drip site.”

Warning signs — come to hospital immediately if you develop any of these:

⚠️ “Difficulty breathing, swelling of the face/lips/tongue/throat, or feeling like your throat is closing — this could be a serious allergic reaction. Go to the nearest hospital immediately.”
⚠️ “Severe skin rash with blisters, peeling skin, or sores in the mouth/eyes — stop the medicine and go to hospital.”
⚠️ “Severe diarrhoea (bloody or very watery, many times a day) with fever and stomach cramps — see your doctor urgently. This can happen even up to 2 months after you finish the course.”
⚠️ “Yellow colour of the eyes or skin (jaundice) — very rare with this medicine, but see your doctor.”
⚠️ “Unusual bruising or bleeding — see your doctor.”
⚠️ “For patients who had eye surgery and received this medicine in the eye: severe eye pain, redness, cloudiness, or sudden loss of vision — contact your eye doctor immediately.”

Things to avoid:

“Do NOT take this medicine on an empty stomach — always take with food.”
“Do NOT crush the tablet — it is very bitter.”
“There is no specific restriction on alcohol, but alcohol may worsen nausea and stomach discomfort. It is best to avoid alcohol while you are unwell with an infection.”
“Do not take antacid medicines (like Digene, Gelusil, etc.) at the same time as this tablet — take the antacid at least 1 hour before or 2 hours after this medicine.”
“Do not take any other medicines (including medicines bought from the chemist without prescription, and any Ayurvedic or herbal medicines) without telling your doctor.”

Storage:

Tablets: “Store at room temperature in a cool, dry place. Keep away from moisture and direct sunlight. Keep out of reach of children.”
Reconstituted oral suspension (liquid): “Store in the fridge after the chemist adds water. If you do not have a fridge, keep it in the coolest part of your house (away from the kitchen, stove, and sunlight). Use within 10 days. Throw away any leftover liquid after 10 days.”
ℹ️ Indian hot climate note: “In summer, the liquid medicine may spoil faster if left at room temperature. Try to keep it cool. If the liquid looks or smells different from when you first got it, do not use it — get a new bottle.”

Duration:

“This medicine is for a specific course to treat your infection — it is NOT a long-term medicine.”
“Your doctor will tell you how many days to take it (usually 5–14 days). Please complete the full course.”
“Do NOT stop early even if you feel better — the infection may come back and be harder to treat.”

Follow-up:

“Come back to your doctor if you are not feeling better after 3 days of taking this medicine.”
“Come back for any blood tests or check-ups your doctor has asked for.”
“If you had a urine infection, your doctor may ask for a repeat urine test after finishing the course to confirm the infection is gone.”

Common Patient Questions:

“Can I take this with my other medicines?”
“Tell your doctor about ALL medicines you are taking. This medicine generally has very few interactions with other drugs — it is one of the safest antibiotics in this regard. But always inform your doctor, especially if you are on blood thinning medicines (warfarin/Acitrom), gout medicines (probenecid), or diabetes medicines.”

“Can I take this during fasting (Ramadan / Navratri / Ekadashi)?”
“This medicine needs to be taken twice a day with food. During fasting, you can take one dose at suhoor/pre-dawn meal and one at iftar/evening meal — this maintains the 12-hour gap AND the food requirement. If your fast does not include any meals, talk to your doctor about an alternative plan. Do NOT take this medicine on an empty stomach.”

“Will this affect my ability to drive or work?”
“No. This medicine does NOT cause drowsiness, dizziness, or confusion. You can drive and work normally while taking it.”

“Is this medicine habit-forming?”
“No. Antibiotics are not habit-forming medicines. You will take them for a specific number of days and then stop.”

“Can I stop once I feel better?”
“No — please complete the full course even if you feel better. Stopping early can allow the infection to come back. The germs may also become resistant, meaning the same medicine may not work next time. This is a very important issue in India where antibiotic resistance is already very high.”

“My child hates the taste of this syrup — what should I do?”
“Yes, this medicine is known to be very bitter-tasting, and many children dislike it. Try giving chocolate or juice immediately after the medicine to wash away the taste. If your child keeps refusing or vomiting the medicine, do NOT force it — call your doctor. They can prescribe a different antibiotic that tastes better and works just as well.”

Caregiver / Family Counselling:

(For paediatric patients, elderly with cognitive impairment, or hospitalised patients)

“Counsel the caregiver/family member on:”

✔ Most important instruction: ALWAYS give with food (tablet or syrup). This is different from many other medicines that are taken on an empty stomach. For this medicine, food is essential — it helps the body absorb the medicine properly.
✔ How to give the correct dose — use the measuring cup or syringe provided, NOT a household spoon.
✔ Timing — twice a day, 12 hours apart, linked to meals (breakfast + dinner).
✔ For liquid: shake well. Store in fridge. Discard after 10 days.
✔ Swallow tablets whole — do NOT crush.
✔ Warning signs to watch for: difficulty breathing, swelling of face, severe rash/blisters, severe diarrhoea, reduced urine output, confusion. Bring to hospital immediately if any of these occur.
✔ Complete the full course — even if the child/patient seems well.
✔ Do NOT share this antibiotic with another family member or save leftover doses for future illness.

India-specific adherence support:

💡 Cost-driven non-adherence:
“If cost is a concern, ask your doctor about generic cefuroxime or medicines from Jan Aushadhi (PMBJP) stores — they are the same medicine at a much lower price. Also ask if a less expensive antibiotic (such as amoxicillin or amoxicillin-clavulanate) would work for your infection.”

💡 Polypharmacy burden:
“If you are taking many medicines, ask your doctor to review which ones are essential. Write down all your medicines and doses on a piece of paper and carry it with you to every doctor visit.”

💡 Temperature-sensitive drug — oral suspension in hot climate:
“The liquid form (suspension) must be kept cool after mixing. In summer, wrap the bottle in a damp cloth and keep in the coolest part of your house if you do not have a fridge. Do not leave it in a car or near a window. The dry powder (before mixing with water) is fine at room temperature.”

💡 Rural access — what to do if you can’t get a refill on time:
“If you cannot get more medicine before your current supply runs out, do NOT reduce the dose to ‘stretch’ the course. Contact your doctor or the nearest Primary Health Centre for help. Do not switch to a different antibiotic on your own.”

💡 Antibiotic stewardship message for patients:
“This is a specific medicine for a specific infection. Do NOT use leftover antibiotics for a future illness or give them to someone else. Using antibiotics unnecessarily or incompletely is a major cause of ‘superbugs’ (resistant germs) — which is a serious problem in India.”

BRANDS AVAILABLE IN INDIA

Jan Aushadhi / PMBJP Brands:

Brand Name	Formulation	Manufacturer / Supplier	Availability
Cefuroxime Sodium Injection (Jan Aushadhi)	750 mg vial, 1.5 g vial	PMBJP-approved supplier (BPPI contracted)	Available at Jan Aushadhi Kendras. Availability may vary by centre.
Cefuroxime Axetil Tablets (Jan Aushadhi)	250 mg, 500 mg	PMBJP-approved supplier	Limited availability — not stocked at all centres.

ℹ️ Jan Aushadhi availability for cefuroxime formulations exists but may not include all strengths or formulations (particularly oral suspension) at all centres. Verify at the nearest Jan Aushadhi Kendra or via the PMBJP website/app (janaushadhi.gov.in).

Major Private Brands:

A. Parenteral (Cefuroxime Sodium — Injection):

Brand Name	Manufacturer	Strengths Available	Availability
Ceftum	GlaxoSmithKline (GSK) Pharmaceuticals India / now Zydus	750 mg vial, 1.5 g vial	Widely available — one of the most recognised cefuroxime brands in India
Supacef	Abbott India (via Piramal Healthcare)	750 mg vial, 1.5 g vial	Widely available
Altacef	Orchid Pharma (now Dhanuka Laboratories)	750 mg vial, 1.5 g vial	Widely available
Zocef	Sun Pharmaceutical Industries	750 mg vial, 1.5 g vial	Widely available
Cefurokind	Mankind Pharma	750 mg vial, 1.5 g vial	Widely available
Curacef	Macleods Pharmaceuticals	750 mg, 1.5 g vial	Widely available
Kefurox / Cefurox	Various	750 mg, 1.5 g vial	Major metros and Tier-2 cities

B. Oral (Cefuroxime Axetil — Tablets and Dry Syrup):

Brand Name	Manufacturer	Formulations Available	Availability
Ceftum	GSK / Zydus	Tablets: 125 mg, 250 mg, 500 mg. Dry syrup: 125 mg/5 mL	Widely available — most recognised oral cefuroxime brand
Supacef	Abbott India	Tablets: 250 mg, 500 mg. Dry syrup: 125 mg/5 mL	Widely available
Altacef	Orchid / Dhanuka	Tablets: 250 mg, 500 mg	Widely available
Zocef	Sun Pharma	Tablets: 250 mg, 500 mg. Dry syrup: 125 mg/5 mL	Widely available
Cefurokind	Mankind Pharma	Tablets: 250 mg, 500 mg	Widely available
Curacef	Macleods	Tablets: 250 mg, 500 mg	Widely available

C. FDC Brands — Cefuroxime Axetil + Clavulanic Acid (Potassium Clavulanate):

Brand Name	Manufacturer	Strengths	Availability	Notes
Ceftum-CV	GSK / Zydus	250 mg + 125 mg, 500 mg + 125 mg tablets	Major metros	ℹ️ Rationality debated (see Formulations section). Not NLEM. Not widely endorsed by Indian guidelines.
Altacef-CV	Orchid / Dhanuka	250 mg + 125 mg, 500 mg + 125 mg tablets	Limited availability	Same debate regarding rationality.

ℹ️ CDSCO regulatory note: As of the latest CDSCO banned drug list (verified against Gazette of India notifications), no cefuroxime single-ingredient formulation has been banned or withdrawn. The cefuroxime + clavulanate FDC is currently marketed and not banned, but its clinical rationality is debated (see Formulations section). No Not of Standard Quality (NSQ) alerts for specific brands listed above are current as of the date of this monograph — however, the CDSCO website should be checked for the latest NSQ alerts.

PRICE RANGE (INR)

Prices as of June 2025. Verify current prices on NPPA/1mg/PharmEasy/Jan Aushadhi price lists as prices may change.

Parenteral — Cefuroxime Sodium (Injection):

Formulation	Strength	Private Retail Price (approx. per vial)	Jan Aushadhi / PMBJP Price (approx. per vial)	NPPA Controlled?
Powder for injection	250 mg vial	₹30–80 per vial	Data limited	ℹ️ Not separately NLEM-listed at 250 mg strength.
Powder for injection	750 mg vial	₹60–180 per vial	₹25–50 per vial	✔ Yes — NLEM-listed. Ceiling price fixed by NPPA under DPCO.
Powder for injection	1.5 g vial	₹120–350 per vial	₹50–100 per vial	✔ Yes — NLEM-listed. Ceiling price fixed by NPPA under DPCO.

Oral — Cefuroxime Axetil:

Formulation	Strength	Private Retail Price (approx. per unit)	Jan Aushadhi / PMBJP Price (approx. per unit)	NPPA Controlled?
Film-coated tablet	125 mg	₹10–25 per tablet	₹5–12 per tablet	❌ Oral cefuroxime axetil is NOT NLEM-listed — NOT under NPPA price ceiling. Prices are market-determined.
Film-coated tablet	250 mg	₹25–55 per tablet	₹12–25 per tablet	❌ Not NLEM-listed.
Film-coated tablet	500 mg	₹50–110 per tablet	₹25–50 per tablet	❌ Not NLEM-listed.
Dry syrup (oral suspension)	125 mg/5 mL (30 mL bottle)	₹50–120 per bottle	Data limited — variable availability	❌ Not NLEM-listed.
Dry syrup (oral suspension)	125 mg/5 mL (50 mL bottle)	₹70–150 per bottle	Data limited	❌ Not NLEM-listed.

Estimated Per-Course / Per-Month Cost:

Clinical Scenario	Dose	Duration	Estimated Private Retail Cost	Estimated Jan Aushadhi Cost
Oral: Mild UTI (adult)	250 mg BD × 5 days (10 tablets)	5 days	₹250–550	₹120–250
Oral: CAP outpatient (adult)	500 mg BD × 7 days (14 tablets)	7 days	₹700–1,540	₹350–700
Oral: AOM (paediatric, ~20 kg child)	15 mg/kg BD (300 mg = ~12 mL BD of 125 mg/5 mL) × 7 days	7 days (1–2 bottles of 50 mL)	₹140–300 per course	Data limited
IV: Moderate infection (adult)	750 mg IV q8h × 5 days (15 vials)	5 days	₹900–2,700	₹375–750
IV: Severe infection (adult)	1.5 g IV q8h × 7 days (21 vials of 1.5 g)	7 days	₹2,520–7,350	₹1,050–2,100
Surgical prophylaxis (single dose)	1.5 g IV × 1	Single dose	₹120–350	₹50–100

💡 Cost comparison with key alternatives:

Drug	Oral Per-Day Cost (typical adult dose)	IV Per-Day Cost (typical adult dose)	Notes
Cefuroxime axetil	₹100–220 (500 mg BD)	₹180–540 (750 mg q8h)	Moderate cost. Oral not NLEM-controlled.
Amoxicillin-clavulanate	₹35–80 (625 mg TDS)	₹120–300 (1.2 g q8h)	✅ NLEM-controlled (oral). Often cheaper. Better anaerobic coverage.
Amoxicillin	₹10–25 (500 mg TDS)	N/A (IV not widely available in India)	✅ NLEM. Cheapest oral option. No beta-lactamase stability.
Cephalexin	₹15–30 (500 mg QDS)	N/A (oral only)	✅ NLEM. Cheap. No H. influenzae coverage.
Cefixime	₹25–70 (200–400 mg OD/BD)	N/A (oral only)	❌ Not NLEM. Broader gram-negative but weaker gram-positive.
Ceftriaxone	N/A (IV/IM only)	₹20–120 (1 g OD)	✅ NLEM. Cheapest parenteral cephalosporin. Once-daily. Broader spectrum → higher resistance selection.
Cefazolin	N/A (IV only; oral step-down = cephalexin)	₹15–60 (1 g q8h)	✅ NLEM. Cheapest IV first-gen. Better MSSA coverage.

ℹ️ Key cost-effectiveness insight: Oral cefuroxime axetil is significantly more expensive than amoxicillin, amoxicillin-clavulanate, and cephalexin. For indications where these cheaper alternatives are equally effective (most community-acquired respiratory infections, uncomplicated SSTIs), cost-conscious prescribing favours the cheaper alternative. Cefuroxime’s main cost-effectiveness advantage is the IV-to-oral step-down within the same molecule — this can reduce hospital stay duration and total cost compared to completing a full IV course of ceftriaxone.

ℹ️ Government supply pricing: Cefuroxime injection (750 mg, 1.5 g) is available through government hospital pharmacies at NLEM-controlled prices. Patients attending government hospitals typically receive injectable cefuroxime free of cost. Oral cefuroxime axetil may or may not be available through government supply (not NLEM-controlled for oral formulation).

CLINICAL PEARLS

💡 1. “TAKE WITH FOOD” — The single most important prescribing instruction for oral cefuroxime, and the commonest reason for apparent treatment failure. [Evidence-based]
Oral cefuroxime axetil bioavailability jumps from ~37% (fasting) to ~52% (fed) — a ~40–50% increase with food. No other commonly used oral cephalosporin has such a large food effect. Many prescribers write “cefuroxime 500 mg BD” without specifying “with food” — and many patients (or their pharmacists) assume antibiotics should be taken on an empty stomach (as is true for ampicillin, cloxacillin, etc.). Result: subtherapeutic levels → failure → unnecessary escalation to ceftriaxone or broader agents. Always write “WITH FOOD” on the prescription. Always counsel the patient verbally.

💡 2. Cefuroxime occupies a critical antimicrobial stewardship niche in Indian practice — use it instead of defaulting to ceftriaxone for non-severe community-acquired infections. [Evidence-based]
Indian hospitals massively overuse ceftriaxone — often for infections that do not require third-generation breadth (non-severe CAP, AOM, sinusitis, mild-moderate SSTI, uncomplicated UTI). Every unnecessary ceftriaxone course selects for ESBL and AmpC resistance. Cefuroxime (IV or oral) covers the same respiratory pathogens (pneumococcus, H. influenzae, M. catarrhalis) as ceftriaxone for non-severe infections, with a narrower spectrum and lower resistance-selection pressure. Ask: “Does this patient need ceftriaxone, or would cefuroxime suffice?” If the answer is cefuroxime, you are practising good stewardship.

💡 3. Myth vs Fact: “Cefuroxime does not work for UTIs in India because of ESBL.”
Myth: Cefuroxime should never be used for UTIs in India.
Fact: Cefuroxime is EFFECTIVE against non-ESBL E. coli and Klebsiella — which still constitute 30–60% of community-acquired uropathogens in many Indian settings. The key is culture-directed therapy: obtain urine C&S, check susceptibility, and use cefuroxime if the organism is susceptible. Cefuroxime should NOT be used empirically for UTI in high-ESBL-prevalence settings without susceptibility data — but it is a perfectly valid choice for culture-confirmed susceptible UTIs, and using it (instead of carbapenems) when appropriate is excellent stewardship. [Evidence-based — ICMR AMR guidelines 2019]

💡 4. The IV-to-oral step-down advantage of cefuroxime — unique among second-generation cephalosporins in India — saves hospital days and costs. [Practice-based]
Cefuroxime is the ONLY cephalosporin in India available as both IV (cefuroxime sodium) and oral (cefuroxime axetil). This allows seamless step-down within the same molecule once the patient is clinically improving, afebrile for 48 hours, and tolerating oral intake. Compare: cefazolin IV → must switch to cephalexin oral (different molecule); ceftriaxone IV → must switch to cefixime oral (different generation with different spectrum and weaker gram-positive coverage). The same-molecule step-down eliminates spectrum uncertainty, simplifies prescribing, and enables earlier discharge. In Indian hospitals with bed scarcity, an early step-down protocol using cefuroxime IV → oral can free up beds and reduce costs.

💡 5. For paediatric prescribing, the bitter taste of cefuroxime suspension is NOT a trivial issue — it is a major barrier to treatment success. [Practice-based]
Indian paediatricians know this well: cefuroxime axetil suspension has one of the worst tastes among commonly prescribed oral antibiotics. Non-adherence due to taste refusal is a significant cause of treatment failure in children. If the child refuses cefuroxime suspension → do NOT persist to the point of caregiver frustration and treatment abandonment. Switch to: amoxicillin-clavulanate (preferred second-line for AOM/sinusitis — better taste), cefpodoxime proxetil suspension (good taste, similar respiratory coverage), or cefixime suspension (excellent taste, good gram-negative coverage but weaker gram-positive). Document the reason for switching (“taste intolerance”) — this is a legitimate clinical decision, not prescriber preference.

💡 6. Cefuroxime has one of the CLEANEST drug interaction profiles of any antibiotic — a significant practical advantage in polypharmacy patients. [Evidence-based]
Zero CYP450 substrate/inhibitor/inducer activity. Zero hepatic metabolism. No significant drug transporter interactions. No warfarin CYP interaction (unlike dicloxacillin/nafcillin — which are CYP inducers and reduce warfarin levels). No calcineurin inhibitor interaction (safe with cyclosporine/tacrolimus — unlike azole antifungals, rifampicin, or macrolides). This makes cefuroxime an excellent choice for elderly patients on multiple medications, transplant recipients on immunosuppressants, and patients on warfarin/acenocoumarol — where drug interactions are a constant concern. The only clinically relevant interaction is the modest gut-flora-mediated INR increase with warfarin/acenocoumarol (pharmacodynamic, predictable, manageable with INR monitoring).

VERSION

RxIndia v0.1 — 16 Mar 2026

REFERENCES

Listed below are the sources actually used or referenced in generating this monograph:

CDSCO Product Insert — Cefuroxime Sodium for Injection and Cefuroxime Axetil Tablets (multiple manufacturers; representative inserts from GlaxoSmithKline Pharmaceuticals India Ltd [Ceftum] and Abbott India Ltd [Supacef]). CDSCO-approved labelling for indications, dosing, contraindications, adverse effects, pharmacokinetics.
Indian Pharmacopoeia 2022 — Indian Pharmacopoeia Commission. Monographs: Cefuroxime Sodium, Cefuroxime Axetil. Drug standards, identification, assay.
National List of Essential Medicines (NLEM) India, 2022 — Ministry of Health and Family Welfare, Government of India. Cefuroxime injection (750 mg, 1.5 g) listed under Section 6.2 (Antibacterials — Beta-lactam medicines). Oral cefuroxime axetil is NOT separately NLEM-listed.
National Formulary of India, 6th Edition (2021) — Indian Pharmacopoeia Commission. Cefuroxime monograph: indications, dosing, adverse effects, pharmacokinetics, renal adjustment.
ICMR Treatment Guidelines for Antimicrobial Use in Common Syndromes, 2019 — Indian Council of Medical Research. Guidance on empirical antibiotic selection for CAP, UTI, SSTI, AOM, sinusitis, and AECOPD. Resistance data for Indian pathogens. Antimicrobial stewardship recommendations. Reference for ESBL prevalence data in Indian uropathogens and respiratory pathogens.
API Textbook of Medicine, 11th Edition — Association of Physicians of India. Chapters on: Community-Acquired Pneumonia, Acute Otitis Media, Acute Bacterial Sinusitis, COPD Exacerbations, Urinary Tract Infections, Skin and Soft Tissue Infections, Surgical Site Infection Prevention, Lyme Disease.
IAP (Indian Academy of Pediatrics) Guidelines:
- IAP Guidelines on Management of Acute Otitis Media in Children (revised edition).
- IAP Guidelines on Paediatric Community-Acquired Pneumonia (revised 2021).
- IAP Guidelines on Urinary Tract Infections in Children.
- IAP Guidelines on Antimicrobial Stewardship in Paediatrics.
NNF (National Neonatology Forum of India) Clinical Practice Guidelines — Neonatal Sepsis: Diagnosis and Management (latest edition). Referenced for neonatal dosing intervals and the recommendation that cefuroxime is NOT first-line for empiric neonatal sepsis.
WHO Pocket Book of Hospital Care for Children, 2nd Edition (2013) — World Health Organization. Paediatric dosing references, pneumonia management guidelines.
FOGSI (Federation of Obstetric and Gynaecological Societies of India) Guidelines — Caesarean section prophylaxis, UTI in pregnancy management.
Goodman & Gilman’s The Pharmacological Basis of Therapeutics, 14th Edition (2023) — Brunton LL, Knollmann BC (editors). Chapter: Penicillins, Cephalosporins, and Other β-Lactam Antibiotics. Pharmacology of cefuroxime, mechanism of action, PK/PD of beta-lactams, spectrum of activity, cephalosporin classification, prodrug pharmacokinetics of cefuroxime axetil, food effect data.
Harrison’s Principles of Internal Medicine, 21st Edition (2022) — Jameson JL, Fauci AS, Kasper DL, et al. (editors). Chapters: Treatment of Bacterial Infections, Pneumonia, UTI, SSTI, Surgical Prophylaxis, Lyme Disease, Otitis Media, Sinusitis, COPD.
AIIMS Treatment Guidelines / Protocols — All India Institute of Medical Sciences, New Delhi. Referenced for: Surgical prophylaxis protocols (orthopaedic, cardiac, general surgery), empirical pneumonia management, antimicrobial stewardship framework.
NCDC (National Centre for Disease Control) Infection Control Guidelines — Referenced for surgical prophylaxis recommendations in Indian hospital settings.
ASHP/IDSA/SIS Clinical Practice Guidelines for Antimicrobial Prophylaxis in Surgery (2013) — Bratzler DW, et al. Am J Health-Syst Pharm; 70:195–283. Referenced for surgical prophylaxis indications, timing, re-dosing intervals, and duration. Adapted for Indian practice.
ESCRS Guidelines for Prevention and Treatment of Endophthalmitis Following Cataract Surgery (2013) — European Society of Cataract and Refractive Surgeons. Referenced for intracameral cefuroxime prophylaxis evidence, dilution protocol, and ESCRS RCT (Barry P, et al. J Cataract Refract Surg 2006; 32:407–410).
GOLD 2024 — Global Initiative for Chronic Obstructive Lung Disease Report — Referenced for AECOPD antibiotic indications and cefuroxime positioning.
IDSA/AAN/ACR Lyme Disease Guidelines (2020) — Lantos PM, et al. Clin Infect Dis; 72:e1–e48. Referenced for cefuroxime axetil as alternative oral therapy for early Lyme disease.
NACO (National AIDS Control Organisation) / ICMR National Treatment Guidelines for Gonorrhoea — Referenced for the recommendation that cefuroxime should NOT be used for gonorrhoea due to widespread resistance; ceftriaxone is current first-line.
NPPA (National Pharmaceutical Pricing Authority) — Drug Price Control Order (DPCO) — Ceiling price notifications for cefuroxime injection formulations. Available at nppaindia.nic.in.
PMBJP (Pradhan Mantri Bhartiya Janaushadhi Pariyojana) — Product catalogue and pricing. Available at janaushadhi.gov.in.
CDSCO Banned Drugs List — Gazette of India notifications on banned/restricted fixed-dose combinations. Reviewed to confirm no cefuroxime single-ingredient or approved FDC ban status.
PvPI (Pharmacovigilance Programme of India) — ADR reporting guidelines and mechanism. Central Drugs Standard Control Organisation. Available at cdsco.gov.in. Helpline: 1800-180-3024.
AIOS (All India Ophthalmological Society) — Endorsement of intracameral cefuroxime for post-cataract endophthalmitis prophylaxis. Referenced for Indian ophthalmology practice context.
Indian Paediatric Nephrology Group (IPNG) Guidelines — UTI management and investigation protocols in children. Referenced for paediatric UTI imaging recommendations.

2nd Generation

Medication Registry

Cefuroxime

Cefaclor

Cefprozil

Explore More

Quick Links